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Prostate cancer patients treated with androgen deprivation therapy (ADT) eventually develop 
castrate-resistant prostate cancer (CRPC).  1,25-dihydroxyvitamin D3 (1,25D3), is a potential 
adjuvant therapy that confers anti-proliferative and pro-differentiation effects in vitro, but has 
had mixed results in clinical trials.  The impact of the tumor microenvironment on 1,25D3 
therapy in CRPC patients has not been assessed.  Transforming growth factor-β (TGF-β), which 
is associated with the development of tumorigenic “reactive stroma” in prostate cancer, induced 
VDR expression in the human WPMY-1 prostate stromal cell line.  Similarly, TGF-β enhanced 
1,25D3-induced upregulation of CYP24A1, which metabolizes of 1,25D3 and thereby limits 
VDR activity. Ablation of Hic-5, a TGF-β-inducible nuclear receptor co-regulator, inhibited 
basal VDR expression, 1,25D3-induced CYP24A1 expression and metabolism of 1,25D3 and 
TGF-β-enhanced CYP24A1 expression.  Luciferase reporter mapping of the CYP24A1 promoter 
identified a Hic-5-responsive sequence 392-451 bp upstream of the transcription start site (TSS).  
Ectopic expression of Hic-5 sensitized LNCaP prostate tumor cells to growth-inhibitory effects 
of 1,25D3 at a lower concentration by a pathway independent of CYP24A1.  The sensitivity of 
Hic-5-expressing LNCaP cells to 1,25D3-induced growth inhibition was accentuated in co-
culture with Hic-5-ablated WPMY-1 cells.  Therefore, my findings suggest that the search for 
mechanisms to sensitize prostate cancer cells to the anti-proliferative effects of VDR ligands 
needs to account for the impact of VDR activity in the tumor microenvironment.  By acting as a 
co-regulator with distinct effects on VDR transactivation in prostate cancer and stromal cells, 
Hic-5 could exert diverse effects on adjuvant therapy designed to exploit VDR activity in 
prostate cancer. 
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1.0  INTRODUCTION 
Prostate cancer is one of the leading causes of cancer among men in the United States.  It 
was the most diagnosed cancer among men in 2011, affecting 241,740 new patients, and 
directly leading to 28,170 deaths, second only to lung cancer (1).  Approximately 1 in 6 
males in the US can expect to develop prostate cancer in their lifetimes.  Increased 
screening for prostate-specific antigen (PSA) in the blood, which is elevated in prostate 
cancer, attributes to the precipitous reduction in the mortality rate and increase of 5-year 
survival rates by allowing for early detection at a phase when the cancer is localized (2). 
Between 1999 and 2006, 80% of diagnoses were at the localized stage, compared to 12% 
with regional metastases and 4% with distant metastases (3).  Patients with cancers 
diagnosed at the localized and regional stages had a 5-year survival rate of 100%, whereas 
those diagnosed with distant metastases had a poor survival rate of 27.8% (4).  Despite the 
increased detection, PSA screening has become controversial due to the number of false 
positives and indolent tumors that it detects (5).  New guidelines established by the 
American Urology Association in April 2013 recommend screening tailored to the 
individual, with high-risk individuals given the option of screening after age 40 and shared 
decision-making on a regimen between ages 55 and 69 to increase quality of life (6). 
The poor survival rate of those diagnosed with and who progress to metastatic 
prostate cancer is due to the lack of effective therapy options to the patient.  Androgen-
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deprivation therapy (which will be discussed later) is only effective for 2-3 years, but 
eventually the cancer becomes castrate-resistant.  Abiraterone acetate, a novel therapeutic to 
be discussed in detail below, increases median progression-free survival time to 27.2 
months with prednisone adjuvant, delaying chemotherapy (7).  Chemotherapy with 
paclitaxel, a microtubule stabilizer, only increases the median survival time to 14 months 
from 9 months, while therapy with docetaxel and estramustine, a genotoxic alkylating agent, 
is only slightly better at 20 months (8).  However, palliative care ultimately becomes the 
only course of treatment after all other therapies fail.  Thus, a novel form of treatment needs 
to be developed to supplement chemotherapy and the novel abiraterone acetate therapy.  In 
this project, I sought to understand the molecular pathways of one such potential treatment: 
1,25-dihydroxycholecalciferol (1,25D3), the active metabolite of Vitamin D, and the 
conditions that sensitize the cancer to it. 
1.1 THE PROSTATE GLAND: STRUCTURE, FUNCTION, AND PATHOLOGY 
1.1.1 Normal development of the gland 
Most male accessory glands, such as the epididymis, vas deferens, and seminal vesicles, develop 
during embryogenesis from the Wolffian ducts, which is a mesodermal structure (9).  However, 
the prostate gland develops from the urogenital sinus (UGS), which has endodermal heritage 
(10). At 9 weeks in fetal human development, the fetal testes initiate production of testosterone 
(T), which can bind to the androgen receptor (AR) in the UGS mesenchyme either intact or 
converted to a more potent form, dihydrotestosterone (DHT), by 5α-reductase (11). Secretion of 
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paracrine factors induces epithelial budding from the UGS that penetrates into the mesenchyme 
in directions dorsal, ventral, and lateral to the bladder (10).  As the epithelial buds mature and 
express AR, paracrine signals to the mesenchyme induce differentiation into the smooth muscle 
cells that compose the mature stroma (11).  Upon maturation, AR expression retreats into the 
muscular sheath immediately surrounding the epithelium and the epithelium itself (12, 13).  In 
adulthood, testosterone secreted from the testes is required to maintain viability of the 
epithelium.(14) 
In the model proposed by McNeal, the human prostate contains four main zones: the 
peripheral zone, the central zone, the transition zone, and the periurethral gland region.  95% of 
the glandular mass is contained within the peripheral and central zones (15).  Differences 
between the central and peripheral zones are indicated in the differing composition of stroma and 
glandular architecture between the two zones, with the central zone having larger ducts in higher 
concentration of ductal arborization of acini and stroma composed of compact smooth muscle 
fibers.  In the peripheral zone, the normal stroma is more loosely woven, with higher abundance 
than in the central zone.  Whereas the central zone has been relegated in clinical circles to a 




 Figure 1: Tumorigenesis in prostate cancer. 
The normal prostate contains well-defined epithelial ducts within a fibromuscular stroma.  As the 
tumor progresses, the epithelium gradually loses its glandular structure until it become 
completely de-differentiated and diffused among the stroma. 
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Cancer (17), copyright 2001.  
License number 3207740131835. 
1.1.2 Neoplasia and carcinogenesis 
The causes of prostate cancer are poorly understood.  Attempts to understand precursors of the 
disease center on proliferative inflammatory atrophy (PIA) and prostatic intraepithelial neoplasia 
(PIN).  Like prostate cancer, PIA arises primarily from the peripheral zone, where it retains 
glandular structure while undergoing proliferation (18).  PIA has the potential to transition to and 
merge with PIN, with 40% of PIN lesions merging with PIA (19).  High-grade PIN is recognized 
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as a precursor to prostate cancer, which loses the delineated glandular structure clearly separated 
by a basement membrane as it transitions to an invasive state (Figure 1) (20). 
Because most prostate cancers are multi-focal, physicians take 8 to 12 core samples from 
the prostate for biopsies, typically from the peripheral zone (21).  The samples are analyzed for 
glandular differentiation and invasion using the Gleason grading system.  Each sample is graded 
on a scale of 1 to 5, by which a Gleason grade 1 indicates well-defined glandular architecture and 
5 a diffuse, de-differentiated tumor.  Two grades are given to each sample for a primary (most 
predominant) grade and a secondary (second most predominant) grade.  The two grades are 
added to give a total Gleason score, which is notated, for example, as 4 + 3 = 7.  Under the 
modifications made to the scale in 2005, the predictive power of the system regarding recurrence 
after radical prostatectomy improved, with a total Gleason score >7 indicating a high risk for 
recurrence (22). 
Not all cancers will necessarily lead to a metastatic state and may remain indolent for the 
lifespan of the patient (23).  For most patients, prostate cancer that is detected at a localized or 
regional stage via PSA screening and biopsy and for whom treatment is indicated can be cured at 
high rates using curative therapies, such as prostatectomy and radiation therapy (3, 4).  However, 
a tumor with a high Gleason score and recurrence of PSA levels post-surgery has a high potential 
to become metastatic, with cells entering the bloodstream via the neovasculature (24).  Primary 
targets of metastasis include the lymph nodes and bone, which provides a fertile “soil” of growth 
factors stored in the bone matrix to the metastatic “seed” (25).  Cross-communication between 
the “seed” and “soil” stimulates the osteoclastic resorption of bone matrix to release  more 
soluble growth factors, increasing metastatic growth, and irregular osteoblastic growth.  The 
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clinical result of these processes is a presentation of pain, increased bone fractures, and spinal-
cord compression (26). 
Currently, therapies for metastatic prostate cancer are limited.  Androgen-deprivation 
therapy and hormone therapies are currently the standard at this stage, but the cancer eventually 
becomes castrate-resistant, and chemotherapy has limited success beyond palliative care (27).  
The problem of castrate resistance and a novel therapy for castrate-resistant prostate cancer 
(CRPC) will be discussed in the subsequent sections. 
1.2 ROLE OF NUCLEAR RECEPTORS IN PROSTATE CANCER 
1.2.1 Nuclear receptor structure and function 
Nuclear receptors are a superfamily of receptor proteins that have descended from a common 
ancestor.  The human genome contains genes coding for 48 known nuclear receptors (28).  These 
receptors directly bind to DNA in the presence of their specific ligand, such as T, estrogen, 
glucocorticoids, and thyroid hormones, although some “orphan receptors” currently have no 
known ligand (29).  A typical nuclear receptor is composed of at least four distinct domains.  The 
highly variable N-terminal domain is responsible for modulation of receptor function, typically 
involving phosphorylation and other modifications like SUMOylation (30).  The DNA-binding 
domain (DBD), the most conserved domain among nuclear receptors, comprises 66-68 amino 
acids that form two zinc fingers, which bind to specific DNA motifs (31, 32).  The hinge domain 
assists in maintaining the structural integrity of the nuclear receptor and, in some cases, contains 
residues whose phosphorylation enhances transactivation of target promoters (33, 34).  The 
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ligand-binding domain (LBD), another structurally conserved domain, comprises 12 conserved 
α-helical regions whose size differs between different ligand types and conformational state 
upon ligand binding (Figure 2) (35). 
 
Figure 2: General structure of a nuclear receptor. 
The N-terminal A domain is variable and confers modulation by covalent modification.  The 
DNA-binding domain (B) is the most conserved domain of the nuclear receptor superfamily.  
The ligand-binding domain (D/E), which is connected to B by the hinge domain (C), changes 
conformation upon ligand binding, facilitating binding to co-regulators. 
 
In the absence of ligand, steroid hormone receptors are associated with a complex of 
chaperone proteins predominantly in the cytoplasm.  The primary component of this complex, 
HSP90, binds to the LBD (36).  HSP90 is required for proper steroid binding to the hydrophobic 
cleft of the LBD, as it creates a stable complex in the LBD at physiological temperatures to 
facilitate binding of the hydrophobic steroid (37).  Other members of the chaperone complex 
include HSP70, p23, and the immunophilin FKBP52 (38).  Ligand binding induces an exposure 
of the nuclear localization sequence and a dynamic state of interaction with the chaperone 
complex that facilitates movement along microtubules by dynein (39).  Nuclear receptors 
residing in the cytoplasm, such as the glucocorticoid receptor (GR), interact with importin-β and 
the nuclear pore glycoprotein Nup62 to facilitate import into the nucleus (38).  However, many 
other nuclear receptors, such as retinoid A receptor (RAR), estrogen receptor (ER), and thyroid 
receptor (TR) constitutively reside within the nucleus (40). 
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Nuclear receptors are classified according to how they bind to their respective ligand 
response elements within the promoter of the target gene, at intergenic sites, or within introns 
(35, 41-44).  Type I receptors, which contain the steroid hormone receptors, bind as homodimers 
at palindromic inverted repeats (45).  Type II receptors, which include TR, RAR, and Vitamin D 
receptor (VDR), bind as heterodimers with retinoid X receptor α (RXRα) at direct repeats (35).  
Most orphan receptors tend to be classified as Type III receptors, which bind as homodimers at 
direct repeats, and Type IV receptors, which bind as monomers at extended core sites (46). 
Co-activators that bind to the AF-2 domain, contained in the most C-terminal part of the 
LBD, confer tissue-specific activation of nuclear receptors.  Additional co-activators may also 
bind at the AF-1 domain close to the N-terminal domain and indirectly through complexes (47).  
Some of these co-activators have acetyltransferase activity (e.g.: SRC-1, CBP/p300) and ATPase 
chromatin remodeling activity (e.g.: TIF1α), opening the chromatin for transcription. Other co-
activators that do not have any intrinsic acetyltransferase or remodeling activity, such as the 
VDR-interacting protein (DRIP) and Hic-5, recruit the transcription initiation complex and serve 
as scaffolding to bridge nuclear receptors to various co-activators (48, 49). 
The most prominent receptor in the prostate is AR.  Its preferential ligand, T, is 
synthesized under the positive control of luteinizing hormone in the Leydig cells of the testes, 
upon which it diffuses to the prostate (50).  However, DHT exhibits 5-fold greater specificity for 
AR, indicating a preference for DHT in situ (51).  In the adult prostate, AR is mainly expressed 
in the secretory cells of the epithelium, with minimal stromal expression (52).  Normal serum 
amounts of T induce a proliferation rate that balances the normal rate of cell death of 1-2% per 
day, maintaining prostate health (53).  Additionally, T supplementation to castrated rats induces 
angiogenesis and vascular survival in the prostate (54).  Withdrawal of androgens or inhibition of 
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their signaling through AR can induce prostatic apoptosis (55).  The following section will 
discuss the biochemical and clinical implications of this process in prostate cancer as well as the 
consequences of failure of treatment. 
1.2.2 Androgen deprivation therapy and castrate-resistant prostate cancer 
While the AR is associated with maintenance of prostate epithelial growth, its aberrant activation 
is also associated with disease development.  Typically, such induction can occur due to presence 
of gene translocations, increased levels of growth factors, deregulated growth pathways, and 
activating mutations with AR itself (56-59).  Androgen-deprivation therapy (ADT) is usually 
indicated as a treatment for patients who have locally advanced or metastatic disease and has 
recently been suggested as an adjuvant with radiation therapy and surgery for patients with 
medium to high risk, according to Gleason score (60, 61).  Anti-androgens, such as bicalutamide, 
compete with androgen for access to AR and inhibit its function (62).  Often, this therapy may be 
given together with a gonadotropin releasing hormone agonist (GnRHa), which induces a high 
release of LH, interrupting its pulsatile secretion and inducing GnRH receptor internalization and 
desensitization (63-65).  While this induces an initial flare, over time LH release decreases, thus 
reducing T synthesis (66). 
The net effect of this therapy is to decrease available T from binding to AR from the 
supply (receptor) and demand (synthesis) sides, thus reducing overall AR signaling.  Reduced 
AR signaling indirectly induces expression of the pro-apoptotic protein Bax to thirteen times its 
normal expression 2 to 3 days after administration, inducing the intrinsic pathway of apoptosis 
(67).  ADT may also induce the extrinsic apoptotic pathway by inhibiting IκB kinase and 
inducing RelA/p65 expression, sensitizing cancer cells to apoptosis-inducing signaling molecules 
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TNF-α, TRAIL, and FasL (68-70).  The principle behind this is the “saturation model”, by which 
a level of T at or near near-castrate levels results in significant reductions in PSA levels (71). 
However, an additional effect of ADT is the upregulation of the anti-apoptotic protein 
Bcl-2.  Unlike the relatively rapid increase of Bax, Bcl-2 increases steadily reaching a peak at 10 
days (72).  Repeated treatment, however, may induce a more permanent induction of Bcl-2 in the 
tumor.  As opposed to 30% of androgen-dependent prostate cancers, almost all CRPCs express 
elevated levels of Bcl-2, suggesting that ADT will eventually contribute to a castrate-resistant 
phenotype, by which the tumor becomes hypersensitive to androgens or loses androgen 
dependence for growth, via this pathway (73).  Additionally, effectiveness of ADT directly on 
AR may be reduced by gene amplification, mutations to a more promiscuous phenotype, and a 
change in balance between AR co-activators and co-repressors (74-76).  Mutations independent 
of AR, such as those in growth pathways, also contribute to CRPC (77).  Patients undergoing 
ADT typically become castrate-resistant at 18-24 months after commencing the therapy (78). 
At this point, treatment options for CRPC are limited.  Recent advances that delay the use 
of chemotherapy, as seen with abiraterone acetate, an inhibitor of androgen synthesis through 17 
α-hydroxylase, have lengthened median progression-free survival time to 27.2 months (7).  
Docetaxel, the current first-line therapy for CRPC, only extends survival to a median of 19 
months (79).  Other treatments do not yet show this length of survival (80).  Thus, there is an 
unmet need to develop additional primary and adjuvant therapies that may be used in androgen-
dependent and castrate-resistant prostate cancer.  One such promising therapy involves Vitamin 
D and its derivatives, which will be discussed in the next section. 
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1.3 THE VITAMIN D RECEPTOR AND ITS IMPACT ON THE PROSTATE 
1.3.1 Synthesis of 1,25-dihydroxycholecalciferol 
In 1919, Kurt Huldschinsky found that exposure of children to radiation from sunlight or a 
mercury-vapor quartz lamp either cured or prevented rickets, a disease that involves softening of 
the bones (81).  A traditional treatment for the disease, cod-liver oil, had been known from the 
folklore of northern Europe.  In 1922, Mellanby and McCollum found that when cod-liver oil 
was heated, it lost its protectiveness against Vitamin A deficiency, but not against rickets.  They 
termed this new substance Vitamin D, as it was the fourth in sequence of vitamins discovered 
(82). Adolf Windaus later discovered that the precursor to Vitamin D is 7-dehydrocholesterol (7-
DHC), found in cod-liver oil by J. Waddell, and that it is activated upon exposure to UV-B 
radiation (82).  In 1980, Michael Holick and Hector DeLuca found that ultraviolet radiation 
penetrates into the stratum spinosum and the stratum basale of the epidermis, inducing the 
photoconversion of 7-DHC to Previtamin D3 by breaking the B-ring of the sterol (83).  Then, 
driven by temperature, Previtamin D3 isomerizes over three days to a more stable form, Vitamin 
D3, also known as cholecalciferol (83).  Production eventually plateaus to 10 to 15 percent of 
original 7-DHC content, at which point the biologically inactive lumisterol accumulates through 
photoisomerization of Previtamin D3, which is then sloughed off with the skin or converted back 
to Previtamin D3 as its stores decrease (84). 
Vitamin D-binding protein (DBP), which prefers Vitamin D3 to lumisterol, facilitates 
transport of Vitamin D3 in the blood to the liver (83, 84).  Within the mitochondrial inner 
membrane and microsomes of hepatocytes, the cytochrome P450 enzyme CYP27A1 
hydroxylates Vitamin D3 at C-25, forming 25-hydroxycholecalciferol (25D3) (85-87).  This is 
 
11 
the major circulating form of Vitamin D3 in the serum (88).  A major site of conversion of 25D3 
is the kidney, where another cytochrome P450 enzyme, CYP27B1, hydroxylates it at the 1α 
position on the A-ring to produce the active form of the vitamin, 1α,25-dihydroxycholecalciferol 
(1,25D3) (Figure 3) (89).  However, CYP27B1 is also expressed in numerous other tissues, 
including the skin, pancreas, brain, lymph nodes, and prostate, where local conversion permits 
autocrine and paracrine signaling (90, 91). 
 
Figure 3: Photosynthesis of 1,25D3. 
7-DHC is converted to Previtamin D3 upon UV irradiation, which isomerizes to Vitamin D3 over 
3 days.  Excess Vitamin D3 is converted to inactive lumisterol upon UV irradiation.  DBP 
binding stabilizes Vitamin D3 for transport in the bloodstream to the liver, where CYP27A1 
converts it to 25D3, and the kidney and other target organs (ie.: the prostate), where CYP27B1 




1.3.2 Structure and activation of the Vitamin D receptor 
The intracellular receptor for 1,25D3 is the Vitamin D receptor (VDR), which is a Class II 
(thyroid receptor-like) nuclear receptor (92, 93). VDR is distributed between the cytoplasm and 
the nucleus, but shifts its localization to be predominantly nuclear upon binding 1,25D3 (94).  
1,25D3 docks into VDR in its 6-S-trans form, oriented equatorially (95).  The C-1α hydroxyl 
group on the A ring coordinates with helices H3 and H5 in the ligand-binding pocket, and the C-
25 hydroxyl group in the aliphatic chain coordinates with helix H12 to activate the AF-2 domain, 
which forms a closed cleft for binding cofactors (96, 97). Unlike other steroid receptors, VDR 
requires heterodimerization with a second receptor, the retinoid X receptor (RXR), in order to 
fully transactivate target genes (98).  In the absence of ligand, a stable VDR/RXR complex, 
which is formed through interactions between H7 on VDR and H7, H10, and H11 in RXR, binds 
weakly to a target Vitamin D response element (VDRE) and recruits a repressive SMRT/nuclear 
co-repressor (NCoR) complex (97, 99).  The SMRT/NCoR complex recruits histone 
deacetylases, impeding transcriptional access to the chromatin.  Binding of 1,25D3 induces 
allosteric changes in the H3 helix of RXR, distant from the heterodimer interface (97).  This 
“phantom ligand effect” allows RXR to recruit cofactors of its own to the VDR/RXR complex 
(98).  The hinge domain between the LBD and DBD facilitates recognition of the VDRE, which 
is a DR3 element consisting of two half-sites of the consensus sequence 5’-AGGTCA-3’ (33).  
VDR binds to the VDRE through two C4 zinc-finger moieties, located at residues 24-44 and 60-
79 (100). 
Ligand activation of the VDR induces changes in the state of the chromatin that are 
dependent on the effect on transcription that VDR has on the target gene.  For genes being 
upregulated, ligand activation of the AF-2 domain and binding to DNA facilitate dissociation of 
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the repressive complex and associations with LXXLL-containing cofactors such as the p160 co-
activators, CBP/p300, and DRIP205 (101, 102).  Formation of the ternary VDR/SRC-
1/NCoA620-SKIP complex facilitates acetylation of histones and de-repression of the chromatin 
(Figure 4) (103).  In turn, Vitamin D receptor interacting proteins (DRIPs) form complexes on 
the AF-2 domain and interact with the transcriptional machinery through TFIIB (104).  
Alternately, liganded VDR may also facilitate transcriptional repression of a promoter.  In this 
case, liganded VDR instead recruits SMRT and NCoR complexes, which in turn recruit histone 
deacetylases (105, 106). 
 
Figure 4: VDR activation pathway.   
1,25D3 diffuses across the plasma membrane and binds with VDR to trigger nuclear localization.  
Liganded VDR forms a heterodimer with RXRα and binds to a VDRE.  The VDR/RXRα 




One VDR target that is induced, the gene encoding for the cytochrome P450 enzyme 
CYP24A1 acts as a negative feedback on VDR activation.  CYP24A1 catalyzes the 
hydroxylation of the C-24 carbon of 1,25D3, rendering it unable to bind to VDR and vulnerable 
to six-step monooxygenation (107).  The final product, calcitroic acid, is water-soluble and 
excreted in the urine (107). 
1.3.3 Molecular effects of Vitamin D in cancer 
Treatment with 1,25D3 in the Dunning rat prostate tumor model resulted in a reduction of tumor 
volume as well as the number and size of lung metastases (108).  Additionally, a prostate-
specific VDR knockout showed reduced cell death and greater proliferation of the prostate than 
their wild-type counterparts, solidifying the roles of VDR and its ligand in controlling cancer 
growth (109).  These preclinical findings have been supported in human clinical trials, which 
exhibited an inverse correlation between prostate levels of 1,25D3 and Ki67, a marker for 
proliferation (110). 
Several pathways have been identified that could contribute to 1,25D3’s effects on 
reducing tumor growth and volume.  One such pathway is cell-cycle inhibition, within which a 
direct target of VDR is the oncogene c-Myc.  For example, in the C4-2 prostate cancer cell line, 
ligand-activated VDR inhibits expression of c-Myc through direct binding to its promoter.  This 
in turn leads to reduced expression of downstream targets of c-Myc such as E2F1, a pro-
proliferative transcription factor, and Bcl-2, an anti-apoptotic protein.  These effects are Rb-
independent (111).  However, knockdown of Rb in LNCaP, the parental cell line of C4-2 cells, 
leads to induction of cyclin E and thus progression of the cell cycle to S phase, indicating 
dependence on Rb in other contexts (112).  Expression of cyclins and cyclin-dependent kinases 
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are also impacted by VDR activation.  For example, CDKN1A, which encodes p21, an inhibitor 
of CDK1 and CDK2, is a VDR target gene.  VDR binding to the CDKN1A promoter in G1 and S 
phases induces acetylation at H3K9, activating CDKN1A transcription and enhancing 
transcriptional activation with p53 (113).  However, this activation is modulated by VDR-
induced transcription of MCM7, which later induces the CDKN1A target miRNA miR-106b 
(113).  Additionally, VDR stabilizes expression of p27, which inhibits CDK2, the kinase 
activated by cyclin E, and retains it in the cytoplasm (114). 
In addition to regulating the cell cycle directly, 1,25D3 and VDR also impact other 
growth signaling pathways through crosstalk.   In the Hedgehog (Hh) pathway, 1,25D3 acts in a 
VDR-independent fashion at the level of the transmembrane G-coupled protein receptor Smo, 
inhibiting transduction of the Hh growth signal and thus preventing Gli-dependent transcription 
of pro-proliferative factors in basal cell carcinoma (115, 116).  Additionally, 1,25D3 treatment of 
primary prostate epithelial and cancer cells demonstrated an early induction of DUSP10, a non-
receptor tyrosine kinase that inactivates the stress-activated protein kinases p38 and JNK (117).  
The canonical MAPK pathway is itself affected when VDR displaces Sp1 from the EGFR 
promoter, downregulating its expression and thus attenuating EGF-mediated cell growth in 
breast cancer cells (118). 
In some contexts, 1,25D3 not only mediates control over growth, but also of apoptosis.  
1,25D3-mediated downregulation of Bcl-2 appears to be the major mediator of apoptosis in 
LNCaP prostate cancer cells, as overexpression of this anti-apoptotic protein inhibits induction 
of apoptosis (119).  In K562 chronic myelogenous leukemia cells, not only is Bcl-2 
downregulated, but Bax, the pro-apoptotic protein it inhibits, is itself induced upon 1,25D3 
treatment, and leading to release of cytochrome c (120).  This ultimately leads to activation of 
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the intrinsic apoptosis pathway through caspase-9 and caspase-3 (121).  However, this is not the 
only apoptotic pathway through which 1,25D3 functions.  Co-treatment of PC-3 prostate cancer 
cells of 1,25D3 with the general cytochrome P450 inhibitor ketoconazole does not induce the 
intrinsic apoptotic pathway, but rather the caspase-8-mediated apoptotic pathway (122).  Also 
implicated in this co-treatment is a caspase-independent pathway through translocation of 
apoptosis-inducing factor (AIF) from the mitochondria to the nucleus, where it binds to DNA 
and induces chromosomal condensation and fragmentation (122-124). 
Not all growth inhibition induced by 1,25D3 treatment is necessarily apoptosis-related, 
but may instead be due to cancer cells adopting a quiescent state.  In conjunction with T 
treatment, 1,25D3 induces greater differentiation of normal rat prostate cells to epithelial tissue 
in correlation with an increase in expression of five nuclear matrix proteins (125).  A direct 
target of VDR, E-cadherin, adheres cells together in junctions, preventing independent 
movement typical of metastasis in colon carcinoma (126).  Accordingly, this also induces 
translocation of β-catenin to the  plasma membrane, where it is sequestered from the Wnt 
pathway in conjunction with rapid VDR signaling to the RhoA/ROCK stress fiber-signaling 
pathway (126, 127).  VDR also induces expression of IGFBP3 as a direct target, confirmed by 
the identification of a VDRE in the promoter (128, 129).  In turn, IGFBP3 inhibits angiogenesis 
and induces p21 expression (130, 131).  IGFBP3 expression is correlated to differentiated state 
of the prostate, with lower expression due to hypermethylation of the promoter correlating with 
aggressiveness of the tumor (132, 133).  1,25D3 also upregulates intracellular interleukin-




Similarly, a VDR agonist can also inhibit progression to pathogenic states, such as cancer 
and fibrosis.  Knockout of VDR in mice rendered their livers susceptible to fibrosis, inducing 
upregulation of transforming growth factor-β (TGF-β), an important mediator of epithelial-to-
mesenchymal transition (EMT) and promoter of fibrosis, upon exposure to CCl4 (135).  
Liganded VDR inhibits the ability of TGF-β to induce fibrosis and EMT upon being recruited by 
Smad3 to TGF-β-target genes that have been epigenetically modified, whereupon it displaces the 
Smad3/Smad4 dimer from the Smad binding element (SBE) (135).  However, this relationship 
between VDR and Smad3 is not universal. In the context of cutaneous injury, TGF-β signaling 
requires liganded VDR in order to have full phosphorylation of Smad3 and normal inflammatory 
response (136).  In a mammalian reporter assay, Smad3 can potentiate VDR-induced 
transactivation (137).  Additionally, an osteocalcin promoter with modifications in spacing 
between the SBE and VDRE exhibited synergistic activation upon co-treatment of TGF-β and 
1,25D3, indicating a VDR/pSmad3 interaction (138).  Thus, the relation of VDR to TGF-β 
signaling is context-dependent. 
In addition to interactions with TGF-β, liganded VDR reduces inflammatory signaling, a 
tumorigenic promoter. For example, interleukin-8 (IL-8) stimulates membrane translocation of 
RhoA, activating the RhoA/ROCK pathway, which then activates NF-κB (139, 140).  In turn, 
NF-κB induces transcription of IL-8, completing the autocrine feed-forward loop (141).  
Ultimately, IL-8 stimulates growth, invasive activity, and metastasis (142). Activated VDR 
inhibits IL-8-induced cell proliferation and NF-κB p65 translocation into the nucleus, in turn 
repressing NF-κB-mediated transcription of IL-8 (139, 141).  Another downstream target of NF-
κB, the prostaglandin synthesis rate-limiting enzyme cyclooxygenase-2 (COX-2), is also 
downregulated upon 1,25D3 treatment (143, 144).  In conjunction with 1,25D3-induced 
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upregulation of the negative prostaglandin regulator 15-hydroxyprostaglandin dehydrogenase 
(15-PGDH), levels of prostaglandin E2 (PGE2), which stimulates migration and invasion, are 
significantly reduced (145, 146).  In a third measure of control on prostaglandins, 1,25D3 also 
represses transcription of the PGE2 target receptor EP2 (145). 
 
Figure 5: UV radiation correlates with incidence of lethal prostate cancer. 
A. First-order trend surface map of UV radiation in the US.  B. First-order trend surface maps of 
prostate cancer mortality by county among white males in the periods 1950-1969 and 1970-1994. 
Springer and Cancer Causes & Control (17(8), 2006, 1091-1101, “UV, latitude, and spatial 
trends in prostate cancer mortality: all sunlight is not the same (United States)”, Schwartz GG, 
Hanchette CL, Figures 1-2) have given permission to reprint figures from the publication in 
which the material was originally published, with kind permission from Srpinger Science and 
Business Media.  License number 3203830438030 (147). 
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1.3.4 Epidemiology and clinical significance of Vitamin D in prostate cancer 
The ability of the prostate to synthesize its own active Vitamin D metabolite has implications 
regarding the relationship between sunlight exposure and development of prostate cancer.  
Geographic epidemiological studies via trend surface analysis with respect to UV exposure in the 
United States between 1950 and 1994 demonstrated a strong correlation between latitude and 
prostate cancer mortality rates, especially north of 40˚N (Figure 5) (147).  This line of 
demarcation is important, because the necessary radiation for Vitamin D3 synthesis is 18 
mJ/cm2, a daily level that is not reached between the months of November to February at this 
latitude (148).  Indeed, diagnosis of skin cancers in the Netherlands correlated with decrease in 
risk of advanced prostate cancer (149).  However, a study in New South Wales, Australia 
observed an increased risk in men who were exposed to high amounts of sunlight in their mid-
adult years, suggesting a potential U-shaped curve at which an optimal level of sunlight protects 
against lethal prostate cancer (150).  While multiple studies have concluded that there is no 
correlation between serum 25D3 levels and overall risk of prostate cancer, recent studies have 
implicated low serum 25D3 levels as a risk factor for aggressive prostate cancer and higher 
mortality (151-155).  At the genetic level, polymorphisms of VDR such as FokI and BsmI, which 
define the restriction sites cut by the respective endonucleases, have also been associated with 
higher mortality (154, 156). 
From the epidemiological studies, it should follow that treatment with high-dose 1,25D3 
(DN-101) could improve prognosis (157).  The Phase II Androgen-Insensitive Prostate Cancer 
(AIPC) Study of Calcitriol Enhancing Taxotere (ASCENT) trial suggested that such treatment 
would be effective as an adjuvant to docetaxel treatment (158).  However, the following Phase 
III ASCENT II trial was disappointing, with the study being halted because the 1,25D3 adjuvant 
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therapy arm had significantly shorter survival than the control group (159).  Two major factors 
affect response to 1,25D3 treatment.  Basal and induced expression of CYP24A1 significantly 
reduces the bioavailability of 1,25D3 (160).  In fact, increased expression of CYP24A1 is 
correlated with poor prognosis in esophageal and lung cancer (161, 162).  In order to compensate 
for this metabolism, higher doses of 1,25D3 may be required in order to induce a 
pharmacological response.  However, high dosage of intravenous 1,25D3 can lead to the 
condition of hypercalcemia.  This increase in serum calcium concentration can cause bone pain, 
nausea, abdominal pain, development of kidney stones, and neuromuscular weakness (163, 164).  
Pre-clinically, ketoconazole, a general cytochrome P450 inhibitor that can inhibit CYP24A1, 
enhances 1,25D3-induced apoptosis in PC3 prostate carcinoma cells (122).  Other levels of 
control may be important.  There have been very few studies on the effects of the tumor 
microenvironment, namely the stroma, on 1,25D3 treatment in prostate cancer.  The importance 
of the microenvironment will be discussed in the following section. 
1.4 MICROENVIRONMENT EFFECTS ON TUMOR GROWTH 
1.4.1 Normal and reactive stroma in prostate cancer 
The Knudson multi-hit hypothesis has traditionally ascribed the major causes of carcinogenesis 
to multiple mutations of proto-oncogenes and tumor-suppressor genes in epithelial cells, leading 
to uncontrolled proliferation (165).  However, mutations within these cells are not sufficient to 
generate tumors.  In a study by Olumi et al., initiated prostate epithelial cells xenografted with 
normal human prostate fibroblasts into mice were unable to form tumors, whereas xenografts 
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containing carcinoma-associated fibroblasts (CAFs) were able to form tumors.  Furthermore, 
CAFs grown with normal human prostate epithelial cells were unable to form tumors (166).  
Similarly, LNCaP cells grafted with normal prostate stroma into mice were rarely tumorigenic, 
and grafts with normal lung stroma did not produce any tumor growth (167).  This correlated 
with the previous finding that rat fetal urogenital sinus mesenchyme (UGM) can induce a bladder 
transitional-cell carcinoma line to accelerate its proliferation in an androgen-inducible manner 
(168).  Together, these results demonstrated the importance of the supporting stromal tissue for 
epithelial growth and development. 
Fetal action of the prostate stroma is derived from the UGM, which directs differentiation 
of the urogenital sinus epithelium (UGE) and prostate development upon androgen stimulation 
(169).  Reciprocally, prostate epithelium induces UGM to differentiate into smooth muscle 
(170).  In the adult human, the stroma comprises a heterogeneous mixture of fibromuscular 
tissue, including fibroblasts, smooth muscle cells, and a collagen-rich extracellular matrix (171).  
The normal stroma produced paracrine factors, such as keratinocyte growth factor (KGF), upon 
T stimulation that promote epithelial development (172, 173).  Paradoxically, high circulating 
levels of T can maintain the adult stroma in a quiescent state (174).  This homeostasis is 
regulated by stromal targets, in which stromal fibroblasts stimulate epithelial proliferation and 
stroma smooth muscle cells inhibit it in response to T (175). 
A disruption in the homeostasis is symptomatic of prostate cancer.  Exposure of prostate 
stroma to PIN, primary, or metastatic tumor epithelium induces a desmoplastic phenotype, in 
which proliferation of stromal cells and deposition of extracellular matrix (ECM) is increased, 
precipitating a “fertile soil” for tumor development (176-178).  The tumor secretes TGF-β to the 
stroma, where it activates stromal fibroblasts from their resting state (179, 180).  The process of 
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transdifferentiation is similar to how fibroblasts are activated in wound healing, in that the 
fibroblasts are transdifferentiated to a myofibroblastic phenotype, expressing smooth muscle 
alpha-actin (SMAA), vimentin, and pro-collagen I (181, 182).  This “reactive stroma”, which 
resembles an overhealing wound, confers a fertile environment for the tumor by paracrine 
expression of factors such as vascular endothelial growth factor (VEGF), fibroblast growth 
factor-2 (FGF2), tumor necrosis factor-α (TNF-α), platelet-derived growth factor (PDGF), and 
KGF (183-185).  These factors improve blood supply to the tumor, increase proliferation, and 
promote migration.  TGF-β also induces its own stroma expression that feeds back onto the 
tumor and promotes EMT (186, 187).  TGF-β also induces a pro-oxidant environment through 
induction of Cox-2, which produces hydrogen peroxide, inhibiting epithelial E-cadherin 
expression and increasing tumor mutagenesis (188).  The reactive stroma further alters the 
microenvironment by remodeling the extracellular matrix, inducing expression of matrix 
metalloproteinase-1 (MMP1), MMP2, MMP3, MMP9, tenascin C, and versican (189-192).  
Together, they break down the basement membrane and inhibit adhesion of tumor cells, allowing 
them to migrate and eventually metastasize to distant sites. 
1.4.2 Hic-5: a stroma-associated receptor cofactor 
Numerous regulators at the transcriptional level modulate stromal response to TGF-β and the 
ensuing reactive-stroma phenotype.  One such important cofactor is Hic-5, which is typically 
localized exclusively to the prostate stroma under normal and malignant conditions (193).  Hic-5 
is derived from Hydrogen peroxide-Inducible Clone-5, referring to one stimulus that induces 
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upregulation of the protein (194).  Additionally, Hic-5 is upregulated by TGF-β signaling, which 
indicates its expression in reactive stroma (76, 193-195). 
 
Figure 6: Hic-5 structure and pathway. 
A.  Hic-5 contains four N-terminal LD domains and four C-terminal LIM domains.  B. Hic-5 
transcription is induced by TGF-β-activated Smad signaling.  Hic-5 then feeds back on the TGF-
β pathway, inhibiting the inhibitory Smad7 and acting as a co-regulator for Smad2 and Smad3.  




Hic-5 belongs to the paxillin family of group III LIM domain-containing proteins, which 
also includes paxillin and leupaxin (196).  The paxillin family of proteins shares a similar 
structure, with amino-terminal (N-terminal) leucine-rich (LD) motifs that vary in number and a 
conserved carboxy-terminal (C-terminal) set for four LIM domains, which are cysteine-rich 
regions composed of two zinc fingers (196-198).  The most common splice variant of Hic-5 
contains four LD domains (Figure 6A) (199).  The family is also characterized by dual 
localizations within the nucleus and at focal adhesions in the cytoplasm (200).  Within focal 
adhesions, Hic-5 functions as an adapter protein, binding to the focal adhesions through its LIM 
domains and inhibiting tyrosine phosphorylation of paxillin by binding to focal adhesion kinase 
(FAK) and protein tyrosine phosphatase-PEST (PTP-PEST) (198, 201, 202).  The net effect of 
this inhibition is modulation of paxillin-mediated transduction of integrin signals, thus inhibiting 
behaviors such as cell spreading (203, 204).  Hic-5 is also a key mediator in TGF-β-induced 
EMT in mouse kidney proximal epithelial tubule cells, mediating RhoA/ROCK-dependent 
stress-fiber formation, which further induces its own expression (205).  Interestingly, Hic-5 is 
required for adhesion formation in three-dimensional ECMs and, with paxillin, for metastasis of 
breast cancer cells (204). 
Under oxidative conditions, the cysteine residues at amino acids 64 and 91 within Hic-5 
are oxidized, decreasing affinity for FAK and PTP-PEST (206).  This leads to an inhibition of a 
potent nuclear export signal (NES) located between residues 64 and 98, thereby enhancing 
nuclear retention of Hic-5 (207).  Within the nucleus, Hic-5 acts as a steroid receptor co-
activator, where it has been implicated in co-activating GR, progesterone receptor (PR), and AR 
(208-210).  It was independently cloned as Androgen Receptor-Associated protein 55 (ARA55) 
as interacting with AR to enhance transcriptional activity (210, 211).  Hic-5 has no intrinsic 
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methyltransferase or histone acetyltransferase activity on its own, but rather acts as a scaffolding 
protein to recruit other cofactors through its FXXLF motifs (212).  In the context of a mammary 
carcinoma cell line, Hic-5 recruits TIF-2 and CBP/p300 to glucocorticoid-responsive genes, such 
as c-fos and p21 (213).  In prostate stromal cells, Hic-5 is necessary for full transactivation of the 
AR target gene KGF (Figure 6B) (193).  Alternatively, in the absence of ligand, Hic-5 recruits 
the NCoR complex, repressing transcription at these sites (213, 214). 
In addition to binding to nuclear receptors, Hic-5 also binds to other transcription factors.  
Hic-5 binds to Sp1 and recruits p300 through its LIM4 domain, enhancing p21 promoter 
transactivation (49).  Additionally, it feeds back onto TGF-β signaling through interaction with 
Smad3.  Interestingly, though, this interaction yields conflicting effects.  In mouse myoblastic 
cells, the Sp1/Hic-5 complex is also bound to Smad3 in p21 promoter transactivation (49).  
However, within rat prostate and LNCaP cells, interaction of the Hic-5 C-terminus with the MH2 
domain of Smad3 results in transcriptional inhibition of Smad3 targets, such as PAI-1 (215).  A 
key protein that may account for the differing effects of Hic-5/Smad3 interaction is Smad7, a 
Smad3 inhibitor.  In PC3 and WPMY-1 cells, Hic-5 inhibits Smad7-mediated inhibition through 
its LIM3 domain, permitting TGF-β-induced phosphorylation of Smad2 and non-Smad TGF-β 
responses (Figure 6B) (216). 
The role of Hic-5 in disease is complex.  In one clinical study, Hic-5 expression was 
higher in some patients with CRPC, correlating with cell-line studies that suggested that Hic-5 is 
upregulated in androgen-hypersensitive cells (217).  Similarly, higher expression of Hic-5 in 
hypertrophic scarring fibroblasts inhibits proliferation but does not induce apoptosis, 
perpetuating fibrosis in hypertrophic scars (218, 219).  However, other clinical studies in prostate 
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cancer demonstrated reduced expression of Hic-5 in stroma that also lost AR expression, a 
phenotype associated with an increased risk of biochemical relapse (220, 221). 
Histological studies have previously shown Hic-5 expression to be predominantly 
stromal, even in advanced prostate cancer (193, 222).  However, new evidence has developed of 
an epithelial role for Hic-5 in the prostate.  Castration of mice induces epithelial expression of 
Hic-5 in normal prostate epithelium (223).  Xenografts of benign and cancerous human prostate 
epithelium in mice also exhibit this induction upon castration (223).  Overexpression of Hic-5 in 
LNCaP (LNCaP/Hic-5) cells reduced tumor growth and invasion and restored castrate 
responsiveness to mixed xenografts containing stroma with a TGF-β receptor 2 (Tgfbr2) 
knockout (223).  Thus, Hic-5 may have an anti-proliferative, anti-tumorigenic role within the 
carcinoma epithelium itself.  However, this is in contrast to expression of Hic-5 in the 
established PC3 cell line (193).  As the PC3 line is also known to be androgen-insensitive, it may 
also be that the patient from which the line was derived was previously treated with castration or 
ADT and thus not reflective of treatment-naïve tumors (224). 
1.5 GOALS OF THIS DISSERTATION 
Previous research into effects of 1,25D3 on prostate stroma has been limited, and there is no 
information regarding the identity or potential biological impact of stromal cell-specific nuclear 
receptor co-regulators (e.g. Hic-5).  Interestingly, the available data indicate that VDR 
expression is reduced in cancer-associated stroma (225).  However, the research does not 
consider the effect of Hic-5, a cofactor of steroid hormone receptors.  Although VDR is 
homologous to other steroid hormone receptors, the effect of Hic-5 on VDR target 
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transactivation has not been examined.  The goals of this project are directed toward 
understanding this potential relation between Hic-5 and VDR and its effect on treatment in 
prostate cancer lines.  In the scope of this dissertation, I reached two goals: 
1. To determine the effect of Hic-5 expression on stromal expression and activity of 
VDR through molecular interactions 
2. To determine the effect of ectopic Hic-5 expression on proliferation and viability 
of a 1,25D3-treated prostate cancer cell line. 
The complex role of Hic-5 in previous research contributes to our current understanding 
of CRPC.  This project outlines a novel association between VDR and Hic-5 that affects 
1,25D3 action in both prostate cancer cells and stromal cells that comprise the tumor 
microenvironment.  Therefore, any future consideration of 1,25D3 treatment in prostate 
cancer will need to consider how co-regulators such as Hic-5 could exert compartment-




2.0  MATERIALS AND METHODS 
2.1 CHEMICALS AND REAGENTS 
Recombinant TGF-β1 was purchased from R&D Systems (Minneapolis, MN) and reconstituted 
in 4.0 mM HCl, according to the manufacturer’s protocol.  1,25D3 was purchased from Cayman 
Chemical (Ann Arbor, MI) and reconstituted to 20 µM in cell culture-grade DMSO.  Specific 
inhibitor of Smad3 (SIS3) was purchased from Sigma (St. Louis, MO) and reconstituted 
according to the manufacturer’s protocol.  A mouse monoclonal anti-Hic-5 antibody (clone 
34/Hic-5) was purchased from BD Biosciences (San Jose, CA).  A mouse monoclonal anti-VDR 
antibody (clone D-6), mouse monoclonal anti-SMAA antibody (clone 1A4), and rabbit 
polyclonal anti-α-tubulin antibody (clone H-300) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Rabbit polyclonal antibodies directed against phospho-Erk1/2 
(clone D13.14.4E) and Erk1/2 (clone 137F5) were purchased from Cell Signaling Technology 
(Beverly, MA).  A mouse monoclonal antibody against GAPDH (clone 71.1) and secondary 
HRP-conjugated antibodies were purchased from Sigma. 
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2.2 CELL CULTURE 
WPMY-1 and PS30 cells are commercially available and were purchased from American Type 
Culture Collection (Rockville, MD).  Scr and shHic-5 cells were generated as described below.  
LNCaP cells transfected with control lentivirus (WT LNCaP) and lentivirus containing murine 
Hic-5 (LNCaP/Hic-5) were obtained as a gift from the laboratory of Neil Bhowmick (Cedars-
Sinai Medical Center, Los Angeles, CA) (223).  Cells were maintained in monolayer in RPMI-
1640 medium containing 5% fetal bovine serum (FBS) (for WPMY-1 cells) or 10% FBS (for 
PS30, WT LNCaP, and LNCaP/Hic-5 cells) and 1% penicillin/streptomycin at 37˚C and 5% 
CO2.  Cells were passaged at ~90% confluence. 
2.3 GENERATION OF STABLE KNOCKDOWN CELLS 
Short-hairpin RNA (shRNA) sequences were designed against Hic-5 (SH1-4) or as a scrambled 
(Scr) control (Table 1).  The oligonucleotides were annealed to form dsDNA and inserted into 
the pHR CMV PURO Wsin18 plasmid after enzymatic digestion by SpeI and PstI.  The plasmids 
were packaged into lentiviral vectors.  WPMY-1 cells were seeded on 6-well cell culture dishes 
at a density of 2.5 x 105 per well for 24 hr before infection.  Lentivirus infection media 
containing polybrene (8 µg/ml) was used to infect the cells for 24 h.  The next day, the media 
was changed, and the cells were cultured for an additional 48 h, trypsinized, and passed to new 
tissue culture dishes.  Cells were then treated with medium containing puromycin (1 μg/ml) for 3 
days.  The resulting pooled colonies were selected, transferred to 96-well dishes, and maintained 
 
30 
in puromycin selection medium.  Pooled colonies were expanded in 30 mm dishes.  The line 
generating the most efficient knockdown (SH2) was renamed shHic-5. 
Table 1: Sequences of shRNA generated against Hic-5 
Construct name shRNA Sequence 
Scr 5'-AAGGGTAGGTTCGACTAGCAGGACTCT-3' 
SH1 5'-GGTTGCTTCATGAACTTAGTGCCAC-3' 
SH2 (shHic-5) 5'-GGAACTTAATTCCACTCAATTCAAC-3' 
SH3 5'-GATCGGTTGCGTCAGGAAATTAATG-3' 
SH4 5'-GAGGACCAGTATGAAGATCAGAAAA-3' 
2.4 RNA MICROARRAY 
Scr and shHic-5 cells were plated at a density of 2.5 x 105 cells per well in a 6-well plate and 
cultured overnight.  The cells were then cultured in serum-free medium for 24 hrs.  The 
following day, they were treated with TGF-β (0, 2.0 ng/mL) and incubated at 37˚C for 10 hrs.  
The medium was then removed, and cells were lysed in 500 µL cold TRIzol (Life Technologies, 
Grand Island, NY).  RNA was extracted using the RNeasy Mini kit (Qiagen, Valencia, CA).  300 
ng of total RNA extracted from each of 5 replicate treatments were analyzed using Affymetrix 
Human Gene 1.0 ST Arrays (Santa Clara, CA).  Bioinformatics were performed in R Statistical 
Software using Bioconductor and the Limma package.  Briefly, array data was normalized using 
RMA, filtered by mapped probes and an arbitrary minimum expression threshold, and genes 
different between groups called by Benjamini-Hochberg adjusted p-values determined from 




2.5 WESTERN BLOT 
5.0*105 WPMY-1 (Scr and shHic-5) or PS30 cells were plated on 65-mm plates and 
grown overnight.  The following day, they were cultured in serum-free medium for ~2 hrs prior 
to the indicated treatment.  At the conclusion of the indicated treatment, whole-cell lysates were 
obtained by lysing WPMY-1 (Scr and shHic-5) and PS30 cells in RIPA buffer (140 mM NaCl, 
0.1% sodium deoxycholate, 10 mM Tris buffered to pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% 
Triton-X, 0.1% SDS, 1 mM NaF, 1 mM PMSF, 100 µM sodium orthovanadate, protease 
inhibitor cocktail (Sigma)) and were quantified by the Lowry assay.  15-20 µg of total protein 
were electrophoresed in a 10% acrylamide gel and transferred to a PVDF membrane (Millipore, 
Billerica, MA) using a Transblot SD Semi-Dry Transfer Cell (Bio-Rad, Hercules, CA).  
Membranes were blocked in 5% dry milk dissolved in phosphate-buffered saline (PBS) 
containing 0.1% Tween-20 (PBS-T) for 30-60 minutes at room temperature on a rotator.  The 
indicated antibody was added to a solution of PBS-T containing 2.5% dry milk at a concentration 
of 1:1000 and incubated on the blot overnight at 4˚C on a rocker.  Membranes were washed three 
times for 5 minutes each in PBS-T, then incubated for 1-2 hrs in a solution of HRP-conjugated 
secondary antibody diluted 1:3000 in PBS-T containing 2.5% dry milk.  Membranes were 
washed an additional three times for 5 minutes each in PBS-T, then incubated with Western 
Lightining ECL chemiluminescent reagent (Perkin-Elmer, Waltham, MA) to detect the HRP 
signal on chemiluminescent film.  Densitometry was analyzed using ImageJ (NIH).  Blots were 
stripped in Re-Blot Plus Strong solution following the manufacturer’s instructions (Millipore) 




2.6 RNA ISOLATION AND REVERSE TRANSCRIPTION-QUANTITATIVE PCR 
Scr and shHic-5 cells were plated in 6-well plates at a density of 1.75 x 105 cells per well and 
were grown overnight.  The next day, they were cultured in serum-free medium for ~2 hr. TGF-
β1 (0, 3.5 ng/mL) and 1,25D3 (0, 100 nM) were added to fresh serum-free medium to add to the 
cells.  The cells were incubated at 37˚C for 6 hrs.  RNA extraction was performed as described, 
with the resulting RNA quantified using the NanoDrop ND-1000 spectrophotometer 
(Wilmington, DE).  Complementary DNA (cDNA) was generated using the High Capacity 
RNA-to-cDNA kit (Applied Biosciences, Carlsbad, CA) according to the kit protocol.  The 
resulting samples were then diluted to 100 µL with nuclease-free water.  Reverse transcription-
quantitative PCR (RT-qPCR) was then performed on the samples with the iTaq Sybr Green 
Supermix with ROX (Bio-Rad) on the Stratagene Mx3000P thermocycler (Cedar Creek, TX) 
with primers directed toward GAPDH, VDR, CYP24A1, and human Hic-5 (Table 1).  Relative 
expression was quantified using the comparative Ct (ddCt) method. 
In a similar experiment, LNCaP and LNCaP/Hic-5 cells were seeded on a 6-well plate at 
a density of 3.0 x 105 cells per well and cultured overnight.  The next day, the cells were treated 
with 1,25D3 (0, 100 nM) for 6 hrs.  RNA extraction and cDNA synthesis were performed as 
described.  RT-qPCR was performed with primers directed toward GAPDH, CYP24A1, and 




Table 2: Primer sequences for RT-qPCR 
Primer set Sequences 
GAPDH Forward: 5'-ATCGTCCACCGCAAATGCTTCTA-3' 
Reverse: 5'-TGTTAGCCATGCCAATCTCATCT-3' 
VDR Forward: 5'-CTGACCCTGGAGACTTTGAC-3' 
Reverse: 5'-TTCCTCTGCACTTCCTCATC-3' 
CYP24A1 Forward: 5'-ACCCAGGTGTTGGGATCCAGTGA-3' 
Reverse: 5'-AGCTCTGCTAATCGGCGACCA-3' 
Hic-5 (human) Forward: 5’-TCAGGAGAGCAGAAGGAGGA-3’ 
Reverse: 5’-GGCTGGAAGATGGTTTTGAA-3’ 
Hic-5 (murine) Forward: 5’- AGGATGCCCATCTCCACCAGGACA-3’ 
Reverse: 5’- AGCACTCGGGGCAAAAGGGAG-3’ 
 
2.7 METABOLISM ASSAY 
Scr and shHic-5 cells were plated at a density of 5.0 x 105 cells per 65-mm dish and were grown 
overnight.  The next day, the cells were cultured in serum-free medium for ~2 hrs.  Cells were 
treated in duplicate with 1,25D3 (0, 100 nM) for 0 or 24 hrs at 37˚C.  Reference treatments in 
cell-free dishes were included to account for spontaneous degradation of 1,25D3.  Cells were 
scraped into medium at each time-point, flash-frozen in liquid nitrogen, and stored at -80˚C prior 
to analysis by LC-MS/MS at the UPCI Clinical Pharmacologicy Analytical Facility.  LC-MS/MS 
was performed as previously described (226). 
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2.8 LUCIFERASE EXPRESSION ASSAY 
Plasmid pCYP24-537 was obtained from the laboratory of Pamela Hershberger (Roswell Park 
Cancer Institute), and plasmids p392, p451, p470, and p496 were obtained from the laboratory of 
David Callen (University of Adelaide) (227). Scr and shHic-5 cells were plated at a density of 
7.5 x 104 cells per well in a 12-well plate and were grown overnight in antibiotic-free medium 
containing 5% FBS.  The following day, the indicated plasmid containing a firefly luciferase 
reporter (0.5 µg/well) (Table 3), a Renilla luciferase plasmid containing a CMV reporter (0.1 
µg/well), and X-tremeGENE lipophilic transfection reagent (5.0 µL/well) (Roche Applied 
Science, Indianapolis, IN) were incubated in OPTIMEM (100 µL/well) for 1 hr.  Cells were then 
transfected with 100 µL of the mixture and incubated overnight.  The following day, the 
transfection medium was removed, and the cells were cultured in serum-free medium for ~2 hrs.  
They were then treated in triplicate with TGF-β1 (0, 3.5 ng/mL) and 1,25D3 (0, 100 nM) and 
incubated for 6 hr at 37˚C.  Cells were lysed and freeze-fractured overnight in the passive lysis 
buffer contained in the Dual-Luciferase Reporter Assay system (Promega, Madison, WI).  
Lysates were analyzed in the Veritas Microplate Luminometer (Promega) using the Dual-
Luciferase kit to record firefly and Renilla readings in relative luminescence units (RLU).  




Table 3: List of luciferase reporter plasmids and their sequence spans 
Plasmid Sequence span 
pCYP24-537 -537 to -5 
p392-luc -392 to +36 
p451-luc -451 to +36 
p470-luc -470 to +36 
p496-luc -496 to +36 
2.9 IN SILICO ANALYSIS OF TRANSCRIPTION FACTORS 
The sequence of the human CYP24A1 promoter from region −496 to -392 bp was 
obtained from RefSeqGene (accession number NG_008334.1) and a search for putative 
transcription factors was performed using the Transcription Element Search System (TESS) 
(228).  Unique sites were analyzed in the literature for previously reported interactions of the 
target transcription factor with Hic-5. 
2.10 PROLIFERATION ASSAY 
LNCaP and LNCaP/Hic-5 cells were plated at 2.5 x 103 cells per well in a 96-well plate for at 
least 18 hr.  The cells were carefully treated in triplicate with 1,25D3 (0, 10, 100 nM) in RPMI 
1640 containing 10% FBS for 0 and 72 hr at 37˚C.  At each time-point, the plate was aspirated 
and frozen overnight at -80˚C.  The next day, the plate was thawed to room temperature.  The 
CyQuant Cell Proliferation Assay kit (Invitrogen) was used to measure nuclear staining.   Each 
well was incubated with the prepared dye mixture (100 µL/well) in the dark for 10 minutes. 
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Fluorescence was read at excitation wavelength of 480 nm and an emission wavelength of 520 
nm on a SpectraMax Gemini EM plate reader (Molecular Devices, Sunnyvale, CA).  Data at 72 
hr was normalized to baseline at 0 hr. 
2.11 CO-CULTURE PROLIFERATION ASSAY 
25-mm circular coverslips were made suitable for co-culture using nail polish to create pedestals.  
Four drops of nail polish were added to each coverslip and then allowed to dry under an 
ultraviolet lamp for additional sterilization for 1 hr.  The coverslips were then placed in 6-well 
dishes and incubated in poly-D-lysine (10 µg/mL) for either 2 hrs at 37˚C or overnight at 4˚C.  
The coverslips were then washed twice in water.  LNCaP and LNCaP/Hic-5 cells were plated at 
1.5 x 105 cells per well and grown overnight.  Simultaneously, Scr and shHic-5 cells were plated 
at 2.0 x 105 cells per well in two other 6-well plates and grown overnight.  The next day, the 
coverslips were moved to the 6-well plates containing the stromal cultures (Figure 7).  Cells from 
two untreated coverslips from each epithelial line were washed in PBS and fixed to the 
coverslips immediately in 4% paraformaldehyde (PFA) at 0 hr to establish a baseline.  The co-
cultures were then treated with 1,25D3 (0, 100 nM) in RPMI 1640 medium containing 10% FBS 
for 72 hrs.  The cells were washed once in PBS and then fixed to the coverslips in 4% PFA.  The 
cells were then permeabilized in PBS containing 0.1% Triton-X.  The cells were washed twice in 
PBS and then incubated with DAPI (1.0 mg/mL) at room temperature.  The cells were washed 
twice in PBS, and the coverslips were mounted on slides using Vectashield medium (Vector 
Laboratories, Burlingame, CA).  The slides were visualized and photographed under 
epifluorescence at 200X using the Olympus IX-81 microscope (Center Valley, PA).  Counts 
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were averaged from 6 fields per coverslip and normalized to the 0-hr time-point for each 
respective epithelial line. 
 
Figure 7: Schematic of co-culture assay. 
Nail polish was placed at four points on the coverslip and dried.  After treatment with poly-D-
lysine, WT LNCaP and LNCaP/Hic-5 cells were plated on the coverslips and grown overnight.  
The next day, the coverslips were overlaid on the stromal layers.  The nail-polish pedestals 
prevent extreme crushing of the stromal layer and permit exchange of paracrine factors into the 
greater medium. 
2.12 CO-CULTURE VIABILITY ASSAY 
18 mm x 18 mm coverslips were prepared as above.  LNCaP/Hic-5, Scr, and shHic-5 cells were 
plated and grown as above.  The co-cultures were treated with 1,25D3 (0, 10 nM) in RPMI-1640 
medium supplemented with 10% FBS and incubated at 37˚C for 72 hrs.  At the end of the 
incubation, the coverslips were moved to another 6-well plate and trypsinized in 1.0 mL trypsin 
for ~1 hr at 37˚C.  The supernatants from the co-cultures were collected in 2.0-mL 
microcentrifuge tubes and centrifuged at 1.0 x 103 g for 10 minutes.  The trypsinized 
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LNCaP/Hic-5 cells were added to their respective supernatant pellets and centrifuged again at 1.0 
x 103 g and 4˚C for 10 minutes.  The pellets were resuspended in 100 µL of medium and stored 
on ice until counting.  Each sample was diluted with 100 µL of Trypan blue (Gibco, Grand 
Island, NY).  10 µL of the sample were loaded into both sides of a hemocytometer.  Dead cells 
were counted in both sides of the hemocytometer under a light microscope by blue stain, whereas 
live cells were counted by dye exclusion.  Three counts of the sample were taken and added 
together.  Viability was determined by dividing the total number of live cells by the total number 
of cells counted. 
2.13 STATISTICAL ANALYSIS 
The UPCI Biostatistics Facility provided assistance with statistical analysis.  Multiple 
comparisons were performed with the two-way or three-way mixed-models ANOVA with 
Satterthwaite approximation, followed by cell-means post-hoc test in SAS (229).  Interval data 
and Western blot data that contained results below detectable levels were left untransformed, 
while ratio data that did not skew close to 0 were log-transformed, and proportion data was logit-
transformed (230).  RT-qPCR analysis was performed on the cycles scale, and confidence 




3.0  RESULTS 
3.1 REGULATION OF VDR EXPRESSION BY TGF-β AND HIC-5 IN WPMY-1 
PROSTATE STROMAL CELLS 
Hic-5 functions as a co-activator of androgen receptor in WPMY-1 prostate stromal 
myofibroblast cells and is an established component of the TGF-β signaling pathway (49, 193, 
215, 216, 219).  To evaluate the impact of Hic-5 on the TGF-β response of WPMY-1 cells, a 
stable knockdown of Hic-5 using a specific, lentivirally encoded shRNA (shHic-5) was 
developed previously in the laboratory by Marjet Heitzer.  Specifically, WPMY-1 cells were 
stably infected with lentivirus encoding either scrambled shRNA (Scr) or shHic-5.  The response 
of generated Scr and shHic-5 lines to TGF-β was assessed by gene expression microarray 10 
hours after treatment with 2.0 ng/mL TGF-β1 with assistance from Melanie Grubisha and Grant 
Buchanan.  Of particular relevance here and shown in Figure 8, VDR was identified in the 
microarray as a TGF-β target whose mRNA expression was reduced upon Hic-5 knockdown.   
Basal expression of VDR was reduced upon Hic-5 knockdown in the microarray, although 
induction by TGF-β1 was retained.  Detailed analysis of Hic-5 dependence of the TGF-β1-





Figure 8: Basal and TGF-β1 induced VDR mRNA expression is reduced upon Hic-5 
knockdown in WPMY-1 cells. 
Scr and shHic-5 cells were treated with TGF-β (0, 2.0 ng/mL) for 10 hrs and, and isolated RNA 
was hybridized to an Affymetrix Human Gene 1.0 ST microarray, which contained 14,267 
human unique cDNA probes.  Boxplots represent quartiles fromfive independent experiments.  




In order to validate the microarray data, TGF-β1 and Hic-5 effects on VDR mRNA and 
protein expression were analyzed respectively using reverse transcription-quantitative PCR (RT-
qPCR) and Western blotting in independent biological samples from Scr and shHic-5 cells.  
Figure 9A and Figure 10A show that expression of Hic-5 mRNA was indeed significantly 
reduced in shHic-5 cells.  The use of 3.5 ng/mL TGF-β1 was optimal for my reagent preparation.   
While treatment of Scr cells with 3.5 ng/mL TGF-β1 induced expression of VDR mRNA 4-fold 
within 6 hours, this induction was inhibited by knockdown of Hic-5.  Likewise, basal expression 
of VDR mRNA was reduced (Figure 9B, Figure 10B).  Immunoblot analyses of Scr and shHic-5 
cells 24h after treatment with or without 10 ng/mL TGF-β1 confirmed the effect of Hic-5 
knockdown on basal and induced levels of VDR protein (Figure 9C-D).  Therefore, Hic-5 
regulates basal and TGF-β1-induced expression of VDR at the mRNA and protein level, 





Figure 9: Hic-5 knockdown reduces basal and TGF-β-induced VDR mRNA and protein 
expression.  
A, B. Scr and shHic-5 cells were serum-starved for 2 hr, then treated for 6 hr with TGF-β1 (0, 
3.5 ng/mL).  mRNA was extracted for cDNA synthesis and RT-qPCR probing for Hic-5 (A), 
VDR (B), and GAPDH expression. Comparisons were made using the comparative Ct (ddCt) 
method.  TGF-β1 induced VDR transcription in both Scr and shHic-5 cells.  Data were analyzed 
with two-way ANOVA with mixed models with cell-means post-test.  Bars represent 
mean±SEM of six independent experiments normalized to basal expression in Scr cells. * p < 
0.05, ** p < 0.01.  C.  Scr and shHic-5 cells were serum-starved for 2 hr, then treated for 24 hr 
with TGF-β1 (0, 10 ng/mL).  Blot is representative of three independent experiments.  D. 
Western blot results were analyzed by densitometry in ImageJ.  TGF-β1 induced VDR 
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expression in both Scr and shHic-5 cells.  Basal expression of VDR in shHic-5 was below 
detectable levels, so the data was not transformed.  Two-way mixed-models ANOVA followed 
by cell-means post-test were performed.   Bars represent mean±SEM of three independent 





Figure 10: 95% confidence intervals of TGF-β1-induced Hic-5 and VDR transcription  
contrasts in WPMY-1 cells. 
Data for expression of (A) Hic-5 and (B) VDR were analyzed with two-way ANOVA with 
mixed models and are represented as 95% confidence intervals.  Contrasts are representative of 
six independent experiments. 1, contrast between treated and untreated Scr.  2, contrast between 
treated and untreated shHic-5.  3, contrast between untreated treated Scr and shHic-5.  4, contrast 




3.2 CROSS-TALK BETWEEN VDR AND TGF-β PATHWAY 
The main effectors of the TGF-β signaling pathway are Smad2 and Smad3, which dimerize with 
Smad4 and translocate to the nucleus, where they act as transcription factors.(231) Smad3 has 
previously been implicated in potentiation of 1,25D3-induced transcription of VDR targets.(137)  
To investigate whether this specific pathway is necessary for VDR induction, Scr cells were 
treated with SIS3, as specific inhibitor of Smad3 phosphorylation, along with TGF-β.  A 10 µM 
pre-incubation of SIS3 inhibited TGF-β-induced phosphorylation of Smad3 the greatest. (Figure 
11A)  Preliminary results indicate that while Smad3 inhibition by SIS3 was able to inhibit 
induction of smooth muscle alpha actin (SMAA), a Smad3 target, it was unable to inhibit VDR 
expression (Figure 11B-C).(232)  Pending confirmation, this would suggest that induction of 






Figure 11: Inhibition of Smad3 phosphorylation does not repress TGF-β-mediated 
induction of VDR.   
A.  Scr cells were pre-incubated with the specific Smad3 inhibitor SIS3 (0, 1, 2, 5, 10 µM) for 1 
hr and treated with 3.75 ng/mL TGF-β for 1 hr prior to harvest of protein.  Analysis of pSmad2/3 
staining indicated that the 10 µM treatment of SIS3 inhibited Smad3 phosphorylation the best.  
B. Scr cells were serum-starved for 2 hr, pre-incubated with SIS3 (0, 10 µM) for 1 hr, then 
treated with 3.75 ng/mL TGF-β for 24 hr.  Cells were lysed in RIPA buffer and subject to 
Western blot for analysis of VDR, smooth muscle alpha-actin (SMAA), and GAPDH expression.  




1,25D3 treatment in lung fibroblasts and epithelial cells demonstrated an anti-fibrotic 
effect, inhibiting expression of TGF-β-induced SMAA.(233)  I sought to examine whether 
1,25D3 exerted a similar anti-fibrotic effect on prostate stromal cells that were naïve to TGF-β 
exposure.  WPMY-1 cells, which have a myofibroblastic phenotype, constitutively express 
SMAA (234).  Therefore, I used the PS30 stromal line, an immortalized fibroblastic cell line 
derived from normal prostate stroma (235).  TGF-β (3.5 ng/mL) induced SMAA 24 hrs after 
treatment in PS30 cells.  However, supplementation of 100 nM 1,25D3 with TGF-β stimulation 
blunted SMAA expression (Figure 12A-B).  This indicates that VDR and the TGF-β effector 
Smad3 interact at the transcriptional level in prostate stromal cells.  In this context, liganded 




 Figure 12: 1,25D3 treatment of PS30 prostate stroma fibroblasts inhibited TGF-β-induced 
expression of SMAA. 
PS30 cells were serum-starved for 2 hr and treated with TGF-β1 (0, 3.5 ng/mL) and 1,25D3 (0, 
10, 100 nM) for 24 hr.  Cells were lysed in RIPA buffer and subject to Western blot analysis for 
expression of SMAA, VDR, and GAPDH.  Blots were analyzed for densitometry.  Bars represent 
mean±SEM of two independent experiments.  Preliminary statistical analysis was performed 





3.3 HIC-5 REGULATES 1,25D3- AND TGF-β1-INDUCED EXPRESSION OF 
CYP24A1 IN PROSTATE STROMAL CELLS 
In osteoblasts and resting-zone chondrocytes, TGF-β regulates the activity of CYP24A1, a target 
of VDR that metabolizes active 1,25D3 to its inactive form (236, 237).  CYP24A1 expression is a 
major barrier to effective 1,25D3 treatment in prostate cancer, metabolizing 1,25D3 to the 
inactive form 1,24,25D3.  This metabolite is further metabolized to calcitroic acid, which is then 
excreted in urine (122).  However, the contribution of stromal cells to 1,25D3 metabolism is not 
currently known, nor have compartment-specific regulators of CYP24A1 expression been 
identified. To discern the effect of TGF-β on CYP24A1 gene expression, Scr cells were co-
treated with 3.5 ng/mL TGF-β and 100 nM 1,25D3 and mRNA expression analyzed by RT-
qPCR.  Whereas treating with TGF-β1 alone minimally induced expression of CYP24A1, co-
treatment with 1,25D3 enhanced CYP24A1 expression 300-fold above baseline and 10-fold 
above treatment with 1,25D3 alone (Figure 13B, Figure 14B).  One source of this enhanced gene 
expression may be the increased induction of VDR itself upon TGF-β treatment.  
Analysis of mRNA expression in shHic-5 cells, which were demonstrated to have 
reduced Hic-5 expression that was not influenced by TGF-β or 1,25D3 treatment (Figure 13A, 
Figure 14A), revealed similar dynamics, with minimal induction of CYP24A1 upon TGF-β1 
treatment, greater induction upon 1,25D3 treatment, and enhanced expression upon co-treatment 
of TGF-β1 and 1,25D3 (Figure 13B, Figure 14B).  Direct comparison of the magnitude of these 
effects between Scr and shHic-5 cells identified a significant reduction in CYP24A1 basal 
expression and a reduced 1,25D3-induced response alone or in combination with TGF-β1.  
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Together, these results indicate that Hic-5 is required for maximal induction of CYP24A1 by 





Figure 13: Hic-5 knockdown in WPMY-1 cells reduced TGF-ß-mediated enhancement of 
1,25D3-induced CYP24A1 expression. 
Scr and shHic-5 cells were serum-starved for 2 hr prior to a 6-hr treatment with TGF-β1 (0, 3.5 
ng/mL) and 1,25D3 (0, 100 nM).  mRNA was extracted for cDNA synthesis and RT-qPCR 
analysis for expression of Hic-5 (A), CYP24A1 (B), and GAPDH.  Comparisons were made 
using the ddCt method.  Results were analyzed with three-way mixed-models ANOVA and cell-
means post-test.  Bars represent mean±SEM of three independent experiments normalized to the 





Figure 14: 95% confidence intervals of Hic-5 and CYP24A1 transcription contrasts in 
1,25D3/TGF-β1 co-treatment in WPMY-1 cells. 
Data for expression of (A) Hic-5 and (B) VDR were analyzed with three-way ANOVA with 
mixed models and are represented as 95% confidence intervals.  Contrasts are representative of 
three independent experiments.  1, contrast between TGF-β1 treatment and no treatment.  2, 
contrast between 1,25D3 treatment and no treatment.  3, contrast between TGF-β1/1,25D3 co-
treatment and no treatment.  4, contrast between TGF-β1/1,25D3 co-treatment and 1,25D3 




Reduced CYP24A1 mRNA expression upon Hic-5 knockdown may limit the auto-
inhibitory effects of 1,25D3 on its own accumulation.  Jan Beumer and Robert Parise from the 
Clinical Pharmacology Analytical Facility assisted with liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) to analyze 1,25D3 concentration using medium and cellular content 
from Scr and shHic-5 cultures.  Upon 24 hours of treatment, the 1,25D3 concentration in Scr 
cells and medium was reduced by 50% (Figure 15).  In contrast, the 1,25D3 concentration in 
shHic-5 cells and medium was only reduced by about 15%.  No spontaneous degradation 
occurred within the cell-free control medium, so the reduction of 1,25D3 in the Scr-associated 
medium was due solely to CYP24A1 activity.  It thus appears that Hic-5 is necessary for optimal 






Figure 15: Hic-5 knockdown reduced CYP24A1 activity in shHic-5 cells.   
Cells were serum-starved for 2 hr prior to treatment with 100 nM 1,25D3 and were harvested at 0 
and 24 hr.  Two cell-free control plates were set up to control for spontaneous degradation.  Cells 
were scraped into their respective medium and flash-frozen in liquid nitrogen prior to mass 
spectrometry analysis.  Boxplots represent data from three independent experiments.  Data was 
analyzed by two-way mixed-models ANOVA followed by cell-means post-tests. * p < 0.05, *** 




3.4 IDENTIFICATION OF A HIC-5-RESPONSIVE ELEMENT WITHIN THE 
CYP24A1 PROMOTER 
Transfection experiments using luciferase reporter constructs were used to determine whether 
Hic-5 affects transcriptional activation from the proximal promoter of CYP24A1.  A luciferase 
reporter construct (pCYP24-537) containing a 532-bp promoter sequence between 537 and 5 bp 
upstream of the transcription start site (TSS) included two known Vitamin D response elements 
(VDREs) located 293 bp and 172 bp upstream of the TSS (238).  pCYP24-537 was transfected 
into Scr and shHic-5 cells and luciferase reporter activity measured upon induction by 1,25D3 
alone or in combination with TGF-β1.  As expected, 1,25D3 induced CYP24A1 promoter-driven 
luciferase reporter activity in Scr cells, while treatment with TGF-β1 alone did not induce 
activity (Figure 16).  However, co-treatment of 1,25D3 and TGF-β in Scr cells enhanced 
luciferase activity above that seen with 1,25D3 treatment alone, revealing a permissive effect 
when TGF-β1 is combined with 1,25D3. However, in shHic-5 cells transfected with pCYP24-
537, treatment with 1,25D3 failed to induce luciferase expression above the baseline, and co-
treatment with TGF-β only triggered a small induction that was significantly lower than for Scr 
cells.  Hic-5 expression is therefore required for efficient VDR-mediated transcription induction 




 Figure 16: Hic-5 knockdown inhibits 1,25D3-induced and TGF-β-enhanced luciferase 
expression from pCYP24-537-luc. 
Scr and shHic-5 cells were transfected with pCYP24-537-luc overnight, serum-starved for 2 hr, 
and treated with TGF-β1 (0, 3.5 ng/mL) and/or 1,25D3 (0, 100 nM) for 6 hr.  Cells were lysed in 
Passive Lysis Buffer and freeze-fractured at -20˚C overnight.  Samples from lysates were 
analyzed for luciferase activity.  Boxplots represent data from two independent experiments 
performed in triplicate.  Data was analyzed using three-way ANOVA with cell-means posttest.   




Recent research at the Callen laboratory demonstrated that 1,25-D3-induced expression 
of a luciferase reporter containing portions of the CYP24A1 promoter is dependent on a sequence 
392 bp to 470 bp upstream of the TSS (227).  Several deletion luciferase constructs that include 
the proximal promoter regions from 496 bp (p496-luc), 470 bp (p470-luc), 451 bp (p451-luc), 
and 392 bp (p392-luc) upstream of the TSS were examined to identify potential sites required for 
Hic-5 co-activation.  Luciferase expression from p496-luc in Scr cells demonstrated enhanced 
expression upon co-treatment of TGF-β and 1,25D3, supporting results obtained from the 
pCYP24-VDRE-luc construct (Figure 17).  However, treatment of 1,25D3 alone or together with 
TGF-β failed to induce minimal luciferase expression above baseline from p392-luc above 
baseline.  The ability to both induce luciferase upon 1,25D3 treatment above minimal levels and 
enhance its expression upon TGF-β co-treatment was restored in p451-luc, which demonstrated 
significant increases in expression above levels seen in p392-luc (p = 0.0002 for contrast of 
1,25D3 treatment alone, p < 0.0001 for contrast of 1,25D3/TGF-β1 co-treatment). Therefore, a 






Figure 17: Mapping of CYP24A1 promoter proximal region required for Hic-5 
coactivation. 
Transfections and treatments were performed as above with p392-luc, p451-luc, p470-luc, and 
p496-luc in Scr cells.  Boxes represent two (p392-luc) or three (p451-luc, p470-luc, p496-luc) 
independent experiments performed in triplicate.  Three-way ANOVA followed by cell-means 




The identified Hic-5-responsive element within the CYP24A1 promoter may involve 
previously unknown interactions with transcription factors other than Smad3 and VDR.  The 
promoter sequence was analyzed in silico using TESS, an online software program developed at 
the University of Pennsylvania as a front-end for the TRANSFAC matrix (228).  Two unique 
sites within the sequence 392-451 bp upstream of the TSS were identified (Figure 18).  They 
correspond to consensus sequences for binding of transcription factors Sp1 and TCF4, which 
have previously been demonstrated to interact with Hic-5 (49, 239).  However, the in silico 
analysis did not detect a consensus Smad-binding element or VDRE, indicating that VDR/Hic-5 
interaction at the CYP24A1 promoter may require binding of additional transcription factors to 






Figure 18: Proposed promoter map for CYP24A1. 





3.5 OVEREXPRESSION OF HIC-5 SENSITIZES EPITHELIAL LNCAP CELLS TO 
THE ANTI-PROLIFERATIVE EFFECTS OF 1,25D3 
Recent studies by the laboratory of Neil Bhowmick have revealed a previously unknown 
function of Hic-5 in prostate epithelial cells.  Within 7 days of castration, Hic-5 expression was 
de-repressed in both endogenous mouse prostate epithelium and tumor xenografts derived from 
prostate cancer patients.  Furthermore, aggressive tumor growth of mixed xenografts generated 
with Tgfbr2 knockout of prostate stroma mixed with LNCaP cells was inhibited upon 
overexpression of murine Hic-5 in LNCaP cells (223).  Thus, ectopic expression of Hic-5 in 
prostate epithelium was associated with reduced tumor growth and was uncovered following 
short-term castration. 
Given my demonstration of Hic-5-mediated enhancement of VDR activity in WPMY-1 
cells, I sought to determine whether overexpression of Hic-5 would sensitize LNCaP cells to 
1,25D3-induced growth inhibition.  I therefore examined the effects of 1,25D3 treatment on 
proliferation of LNCaP and LNCaP/Hic-5 cells using the CyQuant nuclear dye assay.  LNCaP 
and LNCaP/Hic-5 cells were treated with 0, 10, and 100 nM 1,25D3 for 72 hours.  As shown in 
Figure 19, growth of LNCaP cells was significant reduced in response to 100 nM 1,25D3, but 
only minimally at 10 nM.  In contrast, LNCaP/Hic-5 cells experienced significantly greater 
growth inhibition in the presence of 10 nM 1,25D3 than in LNCaP cells.  Furthermore, treatment 
at 100 nM also significantly inhibited growth in LNCaP/Hic-5 cells to a greater extent than in 
LNCaP cells.  Thus, Hic-5 overexpression sensitized LNCaP cells to 1,25D3-induced growth 






Figure 19: Overexpression of Hic-5 sensitizes LNCaP cells to 1,25D3. 
LNCaP and LNCap/Hic-5 cells were treated in triplicate in 96-well plates with 0, 10, and 100 
nM 1,25D3 at 0 and 72 hr.  Upon removal of medium, the plates were frozen overnight at -80˚C.  
Upon thawing, cells were lysed and stained in CyQuant assay buffer and read on a fluorimeter.  
Boxes represent results of five independent experiments performed in triplicate.  Two-way 
ANOVA with mixed models followed by cell-means post-tests were performed on the log-




CYP24A1 expression is correlated with cellular resistance to 1,25D3 treatment (122).  
Given my observation that Hic-5 is required for efficient 1,25D3-induced transcription of 
CYP24A1 in WPMY-1 cells, I expected ectopic Hic-5 expression in LNCaP cells to exhibit more 
potent induction of CYP24A1.  mRNA extracted from LNCaP and LNCaP/Hic-5 cells treated 
with 100 nM 1,25D3 was analyzed by RT-qPCR to test whether the sensitization of LNCaP/Hic-
5 cells to 1,25D3 –induced growth inhibition is attributed to a reduction in CYP24A1 expression.  
100 nM 1,25D3 induced expression of CYP24A1 in LNCaP and LNCaP/Hic-5 cells, but there 
was no significant difference between the two (Figure 20, Figure 21).  Therefore, overexpression 
of Hic-5 in LNCaP cells does not alter the extent of CYP24A1 expression.  The sensitization of 
LNCaP/Hic-5 cells to the anti-proliferative effect of 1,25D3 treatment therefore appears to be 






Figure 20: Hic-5 overexpression did not affect 1,25D3-induced expression of CYP24A1 in 
LNCaP cells. 
LNCaP or LNCaP/Hic-5 cells were treated with 1,25D3 (0, 100 nM) for 6 hr.  mRNA was 
extracted for cDNA synthesis and RT-qPCR.  Comparisons were made using the ddCt method.  
Data were analyzed with two-way mixed-models ANOVA and cell-means post-test.  Bars 
represent mean±SEM from four independent experiments normalized to basal expression in WT 




 Figure 21: 95% confidence interals of Hic-5 and CYP24A1 transcription contrasts in 
1,25D3-treated LNCaP and LNCaP/Hic-5 cells. 
Data for expression of (A) Hic-5 and (B) CYP24A1 were analyzed with two-way ANOVA with 
mixed models and are represented as 95% confidence intervals.  Contrasts are representative of 
four independent experiments.  1, contrast between treated and untreated LNCaP cells.  2, 
contrast between treated and untreated LNCaP/Hic-5 cells.  3, contrast between untreated LNCaP 
and LNCaP/Hic-5 cells.  4, contrast between treated LNCaP and LNCaP/Hic-5 cells.  NS = not 




3.6 COMPARTMENT-SPECIFIC EFFECTS OF HIC-5 ENHANCE GROWTH-
INHIBITORY EFFECTS OF 1,25D3 TREATMENT ON LNCAP CELLS 
As shown above, ectopic Hic-5 expression sensitizes LNCaP cells to enhanced 1,25D3-induced 
growth inhibition by a mechanism apparently independent of CYP24A1 activity.  However, 
knockdown of Hic-5 in WPMY-1 cells reduced the 1,25D3-induced activity of VDR, thus 
reducing CYP24A1 expression and metabolism of 1,25D3.  These findings suggest that reduced 
stromal Hic-5 expression in a two-compartment model system would limit inactivating metabolic 
activity of CYP24A1, further enhancing growth-inhibitory effects of 1,25D3 on LNCaP/Hic-5 
cells (Figure 22A-B).  An in vitro co-culture experiment was therefore designed to test how 
expression of Hic-5 in stromal and/or epithelial cells affected 1,25D3 inhibition of the LNCaP 
and LNCaP/Hic-5 tumor lines.  As shown in Figure 23, proliferation of LNCaP cells was not 
significantly affected by a 72-hr treatment of 100 nM 1,25D3 in co-culture with Scr stromal 
cells.  However, when co-cultured with shHic-5 cells, 1,25D3-induced growth inhibition of 
LNCaP cells was enhanced compared to co-culture with Scr cells.  In contrast, LNCaP/Hic-5 
cells were sensitive to the growth-inhibitory effects of 1,25D3 in co-culture with Scr and shHic-5 
stromal cells, but the inhibition was significantly amplified in co-culture with shHic-5 cells 
(Figure 24).  More importantly, after treatment there were fewer viable LNCaP/Hic-5 cells in co-





Figure 22: Proposed model of Hic-5 impact on VDR action in the tumor microenvironment. 
1,25D3-induced expression of CYP24A1 in Hic-5-expressing stromal cells (A) metabolizes 
1,25D3 to an inactive form, inhibiting its anti-proliferative effects on the tumor.  If Hic-5 is 
depleted in the stromal layer (B), CYP24A1 expression is inhibited, and more active 1,25D3 is 





Figure 23: Knockdown of Hic-5 in WPMY-1 cells sensitizes LNCaP and LNCaP/Hic-5 cells 
to 1,25D3-induced inhibition in co-cultures. 
LNCaP and LNCaP/Hic-5 cells were cultured on coverslips separately from Scr (Scr) and shHic-
5 (SH) cells, then co-cultured in the absence (-) or presence (+) of 1,25D3 (100 nM) for 72 hr, 
fixed to the coverslip, and stained with DAPI.  Cells were counted at six random fields per 
coverslip, averaged, and compared against cell numbers obtained at 0 hr..  Boxplots represent 
data from five independent experiments.  A three-way ANOVA followed by cell-means post-
tests were performed on the log-transformed data. NS = not significant, * p < 0.05, ** p < 0.01, 






Figure 24: Knockdown of Hic-5 in WPMY-1 cells sensitizes LNCaP/Hic-5 cells to enhanced 
1,25D3-induced inhibition in co-cultures. 




The decrease below baseline of LNCaP/Hic-5 cells treated with 1,25D3 in co-culture with 
shHic-5 cells suggested a cytotoxic effect within this co-culture.  To examine this possibility, I 
utilized an alternative approach.  Specifically, LNCaP/Hic-5 cells co-cultured with Scr or shHic-
5 cells were treated with the minimal 10 nM 1,25D3 dose, and instead of being fixed to the 
coverslip, LNCaP/Hic-5 cells were trypsinized and combined with a pellet derived from the 
surrounding co-culture medium.  The cells were then stained with Trypan blue to measure viable 
(Trypan blue-negative) cells.  Consistent between the methods, the results in Figure 25 show that 
even lower doses reduced viability of LNCaP/Hic-5 cells co-cultured with Scr cells, and this was 
enhanced when co-cultured with shHic-5 cells.  This demonstrated that the enhanced 
sensitization of LNCaP/Hic-5 cells co-cultured with shHic-5 cells to 1,25D3 treatment resulted in 




 Figure 25: Knockdown of Hic-5 in WPMY-1 cells sensitizes LNCaP/Hic-5 cells to 1,25D3-
induced cell death in co-culture. 
Co-cultures were set up and treated as previously.  Cell pellets from trypsinized coverslips were 
combined with floating cells in the medium, resuspended, and stained with Trypan blue to assess 
viability.  Boxplots represent four independent experiments.  A two way ANOVA with mixed 
models followed by cell-means post-test were performed on the logit-transformed data.  * < 0.05, 
** < 0.01. 
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4.0  DISCUSSION 
4.1 SUMMARY OF FINDINGS 
The work presented here demonstrates the role of Hic-5, a nuclear receptor co-regulator, in VDR 
expression and activity in the prostate tumor microenvironment.  TGF-β, an upstream regulator 
of Hic-5, induces expression of VDR and enhances 1,25D3-induced expression of CYP24A1, a 
VDR target gene and negative regulator of 1,25D3 in WPMY-1 prostate stromal cells.  
Preliminary work indicates that VDR induction does not depend on Smad3 signaling, suggesting 
the importance of Smad-independent pathways in VDR action.  However, 1,25D3 treatment 
reduced SMAA expression in TGF-β-treated PS30 prostate stroma cell line, which models a 
normal prostate stroma naïve to TGF-β.  Thus, VDR activity within the stromal 
microenvironment affects TGF-β-induced Smad-dependent pathways and may be enhanced by 
Smad-dependent and –independent pathways. 
Hic-5, which is localized to the prostate stroma, is required for basal VDR expression in 
WPMY-1 cells.  Knockdown of Hic-5 inhibited 1,25D3-induced transcription of CYP24A1, 
allowing 1,25D3 to accumulate in the culture medium without being metabolized.  From deletion 
analysis of the CYP24A1 promoter, I identified a Hic-5-responsive sequence at 392-451 bp 
upstream of the TSS.  In silico analysis found two putative binding sites for AP-2/Sp1 and TCF4, 
two transcription factors known to interact with Hic-5. 
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Ectopic Hic-5 expression in the LNCaP prostate tumor line sensitized 1,25D3-induced 
growth inhibition at lower concentrations independent of CYP24A1 activity.  From the above 
data, I was able to design a model in which stromal expression of Hic-5 metabolizes 1,25D3 to 
levels that cannot induce growth inhibition in prostate tumor cell line.  However, epithelial 
expression of Hic-5 sensitizes the tumor line to the lower 1,25D3 concentration and enhanced 
growth inhibition upon ablation of stromal Hic-5 (Figure 22).  The model was supported by 
results from my in vitro co-culture proliferation assay.  Furthermore, 1,25D3 not only reduced 
proliferation, but also reduced viability of LNCaP/Hic-5 cells in co-culture with WPMY-1 cells 
ablated of Hic-5.  Therefore, Hic-5 expression differentially regulates VDR effects between the 
epithelial and stromal compartments in prostate cancer. 
4.2 EFFECTS OF TGF-β ON VDR EXPRESSION AND ACTIVITY IN THE 
MICROENVIRONMENT 
Previous studies examining VDR expression in prostate stromal cells had focused on comparing 
normal stroma-associated fibroblasts with cancer-associated fibroblasts (CAFs).  Those studies 
had concluded that VDR expression was comparable in CAFs and normal stroma-associated 
fibroblasts (225).  However, examination of dendritic-cell differentiation to Langerhans cells 
demonstrated that treatment of myeloid cells with TGF-β induced VDR expression.(240)  This 
presented a dichotomy, as prostate cancer cells typically express high levels of TGF-β, which in 
turn induces stromal fibroblasts to undergo transdifferentiation to myofibroblasts, a characteristic 
of reactive stroma (179).  I found that TGF-β treatment of the WPMY-1 stromal cell line induced 
VDR expression.  
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An interesting consequence of TGF-β treatment on WPMY-1 cells is a permissive 
enhancement of 1,25D3-induced CYP24A1 transcription.  TGF-β was previously found to induce 
CYP24A1 expression in resting-zone chondrocytes and osteoblast-like cell lines, but its effect on 
enhancement on 1,25D3-induced transcription was only observed upon pre-incubation of TGF-
β (236, 237).  An increase in CYP24A1 expression in the tumor microenvironment would 
increase metabolism of 1,25D3 and therefore decrease its availability to the tumor (160).  
Therefore, high tumor and stromal expression of TGF-β may negatively impact 1,25D3 therapy.  
The consequences of stromal VDR expression, especially under the influence of TGF-β, have 
not been previously examined in conjunction with clinical trials, and it may be a contributing 
factor influencing the outcomes of clinical trials, such as ASCENT, which yielded mixed results 
in Phase II and III trials (159). 
4.3 HIC-5 AS A STROMAL REGULATOR OF VDR EXPRESSION AND ACTIVITY 
Despite playing an active role in mediating transactivation of nuclear receptor targets, the 
co-regulator Hic-5 has not yet been found to regulate nuclear receptor expression.  My study 
provides the first evidence of Hic-5 as a co-regulator of VDR expression as well as its activity.  
Hic-5 knockdown reduced basal and TGF-β-induced VDR expression.  The mechanisms 
responsible for Hic-5-mediated VDR expression, both basal and TGF-β mediated, have yet to be 
defined, but may utilize Smad transcription factors, which have been previously shown to 
interact with Hic-5 (49, 215).  However, my preliminary research from suggests that TGF-β-
induced expression of VDR is not dependent on Smad3 signaling.  Moreover, treatment of 
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osteoblasts with 1,25D3 actually decreased expression of Smad2 in osteoblasts.(241)  Further 
studies may therefore be focused on potential Smad-independent TGF-β signaling pathways 
which may impact on Hic-5 regulation of VDR expression. 
In addition to affecting VDR expression, Hic-5 also impacts 1,25D3-induced 
transactivation of the CYP24A1 promoter, with reduced CYP24A1 expression upon Hic-5 
silencing.  This extends the range of Hic-5 targets within the nuclear receptor superfamily 
beyond AR, GR, and PR (193, 209, 213).  In the WPMY-1 prostate stromal cell line, Hic-5 acts 
as an AR co-activator that influences expression of paracrine factors, such as KGF, which in turn 
affect the neighboring tumor (193).  The consequence of decreased 1,25D3-induced CYP24A1 
expression upon Hic-5 knockdown is increased accumulation of unmetabolized 1,25D3 in the 
culture medium.  If this mechanism were applied to a clinical condition, reduced stromal Hic-5 
expression may enhance therapeutic benefit of 1,25D3 for patients with prostate cancer by 
prolonging its bioavailability (220, 221).  Although Hic-5 knockdown completely inhibited VDR 
transactivation of the proximal CYP24A1 promoter in transiently transfected cells, induction of 
endogenous CYP24A1 was significantly reduced, but not completely inhibited upon Hic-5 
knockdown upon TGF-β co-treatment with 1,25D3.  Nonetheless, the reduction of CYP24A1 
expression was functionally significant, as 1,25D3 metabolism was dramatically reduced in 
shHic-5 cells. 
Hic-5 does not interact directly with DNA, but it may bind to multiple transcription 
factors in complex, thus acting as a bridge between transcription factors binding at multiple sites 
throughout the promoter.  Deletion analysis revealed a region of importance at 392-451 bp 
upstream from the transcription start site.  Despite the presence of confirmed VDREs in p392, 
these sequences were not sufficient to induce transcription.  In silico analysis of the -392 to -451 
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bp region of the CYP24A1 promoter using TESS did not reveal a traditional VDRE, but instead 
indicated two potential Hic-5 targets (Figure 17) (227, 238).  One proposed site at 445 to 452 bp 
upstream of the TSS showed high homology with the AP-2/Sp1 binding sequence. Sp1 
knockdown is associated with reduction in 1,25D3-induced CYP24A1 expression, and Hic-5 
itself is a co-activator of Sp1 (49, 242).  Additionally, a putative Sp1 site has been previously 
reported (243).  Another site identified at 420 to 424 bp upstream of the TSS shares high 
homology with the TCF/LEF consensus binding sequence.  Hic-5 has previously been 
demonstrated to interact with TCF4, but in this case it functions to repress TCF4 transcriptional 
activation (223, 239).  Thus, the cytosolic function of Hic-5 as a scaffolding protein may extend 
to its nuclear receptor co-factor function, bridging VDR binding within target genes to other 
transcription factors. 
4.4 DIFFERENTIAL HIC-5 EFFECTS IN TUMOR EPITHELIUM AND 
SENSITIZATION TO THERAPY 
Although Hic-5 expression is mainly confined to the stromal compartment in the prostate, 
it is de-repressed upon short-term castration in mouse prostate epithelium and human prostate 
xenografts in mice (193, 223).  Furthermore, as shown here, ectopic Hic-5 expression also 
enhances VDR activity in the LNCaP human prostate cancer cell line, leading to enhanced 
sensitivity to 1,25D3-induced growth inhibition.  This enhanced sensitivity may also be 
influenced by the lack of Hic-5 effects on CYP24A1 expression in LNCaP cells, highlighting the 
cell-specific effects of Hic-5 as a VDR co-activator.  Genome-wide analysis comparing the VDR 
cistrome and transcriptome in prostate cancer and stromal cells with altered Hic-5 expression 
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will enhance my understanding of the seemingly paradoxical cell-specific transcriptional co-
activation of VDR targets by Hic-5. 
The distinct consequences of Hic-5 co-activation of VDR in prostate cancer (reduced 
proliferation) versus stromal (increased 1,25D3 metabolism) cells provide the context for 
examining cancer cell/stromal cell co-cultures as an in vitro mimic of the tumor 
microenvironment. As I demonstrated above, the most potent anti-proliferative effects of 1,25D3 
on LNCaP cells occurs when they ectopically express Hic-5 and are co-cultured with stromal 
cells ablated of Hic-5.  I predict that this is due to the reduced stroma-mediated CYP24A1 
activity, reducing metabolism of 1,25D3, coupled with enhanced VDR regulation of anti-
proliferation genes upon co-activation by ectopic Hic-5 expression.  Regulation of Bax and Bcl-
2, two target genes associated with apoptosis, may account for the enhanced 1,25-D3-induced 
cytotoxic activity observed in LNCaP cells ectopically expressing Hic-5 and co-cultured with 
stromal cells ablated of Hic-5 (67, 120). 
4.5 LIMITATIONS OF RESEARCH 
My results demonstrated a role for the nuclear receptor co-regulator Hic-5 in regulating VDR 
expression and activity in WPMY-1 prostate stromal cells and sensitization to 1,25D3-induced 
growth inhibition in LNCaP cells.   However, VDR expression is not solely dependent upon Hic-
5, as silencing of Hic-5 within WPMY-1 cells did not affect TGF-β induction of VDR expression 
or its synergistic activation with 1,25D3 of CYP24A1 gene expression.  This correlates with a 
preliminary observation that upregulation of VDR is not dependent on Smad3 signaling.  Given 
the role of Hic-5 in the Smad-dependent response to TGF-β treatment, I hypothesize that TGF-β 
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contributes to VDR induction by Smad-independent pathways, such as through ERK, JNK, and 
p38, in the Hic-5-silenced cells (49, 215, 244).  Further experiments investigating 1,25D3 
metabolism upon TGF-β treatment will clarify the biological effects of the Smad-independent 
pathways on 1,25D3 action. 
I also found that co-culturing Hic-5-silenced WPMY-1 cells sensitized Hic-5-
overexpressing LNCaP cells to enhanced cell death, as measured by the Trypan blue exclusion 
assay.  However, this result does not tell us what cell-death pathway is being activated.  
Experiments to analyze induction of the intrinsic apoptosis pathway through caspase-3 cleavage 
were unsuccessful.  However, expression of Bcl-2, an upstream mitochondrial target whose 
overexpression blocks 1,25D3-mediated growth inhibition, should be investigated (119, 120).  
Additionally, I cannot rule out the action of other pro-apoptotic proteins, such as caspase-8, Bid, 
and AIF (122).   
The greatest limitation of my studies relates to the fact that the experiments were 
performed in specific cell lines, which maintain specific characteristics.  For example, the 
LNCaP cell line is AR-positive, is dependent on androgens for survival, and does not express 
5α-reductase (245, 246).  One sub-line of LNCaP, C4-2, is androgen-insensitive and expresses 
low levels of p53 (247).  Ectopic expression of Hic-5 in this cell line will be necessary to 
investigate whether a functional AR is important to 1,25D3 response, activation of VDR and its 
associated co-factors, or upregulation of CYP24A1.  Additionally, mouse xenografts with 
LNCaP tend to develop small tumors, so that growth of stromal cells mixed with them may 
outpace growth of the tumor cell line, preventing formation of a palpable tumor.(223)  Neil 
Bhowmick, my collaborator at UCLA, noticed this in his studies.  The RWPE-2 line, an 
androgen-sensitive prostate tumor line that is derived from the immortalized benign RWPE-1 
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line upon transformation with Ki-Ras, forms palpable tumors upon grafting into nude mice 
(248).  Thus, the RWPE-2 line may prove useful in developing a palpable tumor that ectopically 
expresses Hic-5 and extends my research beyond the context of one cell line. 
To extend my results into translational studies, use of primary cell cultures will be 
necessary.  Data obtained from cell lines may not accurately model prostate cancer as observed 
in therapy-naïve patients, who may contain heterogeneous genotypes.  Therefore, ectopic 
expression of Hic-5 within primary tumor cultures will be important for xenograft formation to 
model disease progression as observed in patients and potential treatment outcomes upon 1,25D3 
therapy.  This would not just apply to primary tumor cultures, but also to derivation of CAFs to 
model a stromal microenvironment developed in vivo.  Previously, other members of the 
DeFranco laboratory have had difficulty expressing an shRNA construct directed against Hic-5 
in primary stromal cells using lentiviral techniques.  Recent studies, however, have demonstrated 
success in silencing Dkk-3 in primary prostate stromal cells (PrSCs) (249).  The lentivirus 
technique used in this study may be useful for achieving the goal of developing a stable 
knockdown in primary stromal lines. 
Overall, my work presented here demonstrates differential function of a co-regulator on 
1,25D3 response in the tumor and stromal microenvironments of prostate cancer.  This presents a 
new area of therapy that needs to be investigated further. 
4.6 CLINICAL SIGNIFICANCE 
One of the main themes of this project was to examine the relevance of the stromal 
microenvironment to 1,25D3 metabolism and VDR activity in prostate cancer cells.  As 
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demonstrated from my results, expression of Hic-5 in prostate stromal cells is necessary for 
efficient 1,25D3-induced transcription of CYP24A1, which in turn metabolizes the compound to 
an inactive form.  One study demonstrated that high expression of Hic-5 was correlated with 
castration resistance and androgen hypersensitivity in late-stage prostate cancer (217).  
Intriguingly, the DU145 cell line, which was derived from a brain metastasis of CRPC, expresses 
high amounts of CYP24A1 and is intrinsically resistant to 1,25D3 treatment (250).  Although 
CYP24A1 expression in CRPC-associated stroma has not yet been researched, it is likely that 
castrate resistance may also influence CYP24A1 metabolism of 1,25D3 and thus resistance to 
therapy.  The inconsistent data of the ASCENT trials supports this hypothesis, indicating that 
adjuvant therapy with taxotere chemotherapy in CRPC may not be successful. 
Instead, my data suggests that a more appropriate period to treat patients with 1,25D3 is 
during ADT.  Previous studies demonstrated that castration of mice de-repressed Hic-5 
expression in the epithelium of endogenous prostate and xenografts from cancer patients (223).  
Furthermore, ectopic expression in LNCaP cells inhibited growth and invasion of a mixed 
epithelial-stromal xenograft (223).  My data demonstrated that ectopic Hic-5 expression 
sensitized LNCaP cells to 1,25D3-induced growth inhibition at lower concentrations.  From this, 
I hypothesize that maximum therapeutic benefit of 1,25D3 may be achieved during ADT, when 
epithelial Hic-5 de-repression may occur.  Such a therapeutic regimen may require less 1,25D3 in 
order to achieve benefit, thus reducing the risk of hypercalcemia.  This assertion is supported by 
a study in which the anti-androgen Casodex failed to inhibit 1,25D3-induced growth inhibition in 
an androgen-independent derivative of the LNCaP cell line (251).  However, additional studies 
had found that Casodex did inhibit 1,25D3-induced growth inhibition in the parental cell line 
(252).  Furthermore, data on tumor expression of Hic-5 is inconsistent and do not distinguish 
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between epithelial and stromal expression of Hic-5 (Table 4) (217, 220, 221, 253, 254).  
Therefore, care must be taken to ensure that 1,25D3 adjuvant therapy to ADT confers maximal 
benefit in a preclinical in vivo model. 
Table 4: List of clinical studies for Hic-5 expression in prostate cancer. 
Author Source Treatment State Hic-5 expression Citation 
Mestayer 
(2003) 
Tumor, benign None Naïve Decreased in tumor (253) 
Fujimoto 
(2001) 





Tumor None, ADT Naïve, 
CRPC 
Decreased in CRPC, 
but higher expression 









None, ADT Naïve, 
CRPC 
Increased in tumors 














Decreased in stroma 
correlated with shorter 
period to CRPC state 
(220) 
4.7 FUTURE DIRECTIONS 
The general theme demonstrated within this work relates to the novel function of a nuclear 
receptor co-regulator within the stromal microenvironment of prostate cancer.  In addition to 
providing the tumor a source of growth factors and a fertile matrix for invasion, the tumor 
microenvironment has recently been shown to secrete growth factors in the presence of 
chemotherapeutic compounds, inducing the acquisition of drug resistance within the tumor 
(255).  Hic-5 expression in the prostate stroma contributes to intratumoral 1,25D3 resistance by 
co-activating the CYP24A1 autoinhibitory metabolic feedback loop.  Expression within the tumor 
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itself, however, confers enhanced sensitization to 1,25D3-induced growth inhibition.  Differences 
in expression of other co-regulators between the tumor and the stroma, such as an altered balance 
between p160-family co-activators and co-repressors, may contribute to the differing action of 
Hic-5 in the two compartments (256).  Based on the work presented here, I hypothesize that Hic-
5 recruits different co-regulators to its target nuclear receptor depending on the context of the 
promoter and cell type. 
At the level of the CYP24A1 promoter, a Hic-5 responsive element was identified at 392-
451 bp upstream of the TSS and was associated via in silico analysis with motifs for AP-2/Sp1 
and TCF4 binding.  Sp1 and TCF4 have previously been associated with Hic-5 binding, although 
in opposing effects (49, 223, 239).  To target these specific sites, I propose a mutation reporter 
assay in which the individual sites are mutated to a string of bases that do not resemble any 
consensus binding motifs for VDR, AP-2/Sp1, or TCF4.  The result of this experiment would be 
not only identifying potential Hic-5 interacting partners at the locus, but also identifying other 
novel regulators of CYP24A1 transcription.  From this, I would investigate additional cross-talk 
pathways that may mediate metabolism of 1,25D3, which may eventually lead to further 
adjuvant therapy to reduce metabolism and prolong bioavailability. 
Advanced technologies like ChIP-seq (chromatin immunoprecipitation with sequencing) 
have facilitated whole-genome identification of unique cis-acting DNA sequences that are bound 
by trans-acting transcription factors and co-regulators.  The unique pattern of these sites, the 
cistrome, creates a signature by which cell-type effects may be identified.  Different patterns of 
binding sites may indicate prognosis of disease (257).  The VDR cistrome describing binding of 
co-activators and co-repressors has recently been described in a colon cancer line (258).  
However, no genome-wide study has yet been performed to identify the VDR cistrome in 
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prostate cancer cells loci of Hic-5-responsive elements.  My data suggests that Hic-5 bridges 
different transcription factors to facilitate cross-talk, enhancing their effects.  Utilizing ChIP-seq, 
I would seek to understand the specific interaction dynamics between Hic-5 and liganded VDR 
within prostate stromal and tumor cells.  Specifically, I have had difficulty with traditional ChIP-
PCR due to the high G/C content (76%) within the identified target sequence in the CYP24A1 
promoter at 392-451 bp upstream of the TSS.  Whole-genome techniques such as ChIP-seq may 
improve processivity and fidelity at this site and identify other sites where VDR interacts with 
Hic-5.  Additionally, I also propose identifying the effect of Hic-5 on binding stability of VDR at 
VDREs.  However, it must be cautioned that VDR may bind to VDREs in a ligand-independent 
manner (259).  Therefore, ChIP-seq analysis will also examine binding of RNA polymerase II 
and co-activator complexes with VDR to examine whether Hic-5 interaction is required for 
recruitment and maximal transactivation. 
Hic-5 binding within the VDR cistrome may influence how VDR target genes are 
expressed throughout the genome.  While my research demonstrates a requirement of Hic-5 
expression for full VDR transactivation of CYP24A1, this may not be the case at other target 
sites.  At the MYC promoter, which VDR negatively regulates, Hic-5 binds to TCF4, inhibiting 
MYC transcription (126, 223).  Thus, the result may be enhanced VDR activity in both 
transcriptional activation and repression.  Whole-genome microarray analysis of the VDR 
transcriptome in Hic-5-ablated cells may point to novel sites of interaction and enhancement as 
well as downstream effects.  Indeed, it may also be possible that Hic-5 expression may 
antagonize 1,25D3-induced transcription or repression of VDR target genes, depending on the 
context of the cell line.  Thus, I propose that microarray analysis be performed in a cell line 
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ablated of Hic-5 expression (for example, comparing stromal Scr to shHic-5) and another line 
with ectopic Hic-5 expression (for example, comparing epithelial LNCaP to LNCaP/Hic-5). 
While my results have demonstrated associations between Hic-5 and VDR, I have not yet 
been able to demonstrate physical interactions between Hic-5 and VDR.  A major impediment in 
my attempts at co-immunoprecipitation (co-IP) in Scr cells was that the molecular weights of 
VDR and Hic-5 are approximately 55 kDa, similar to the molecular weight for the heavy chains 
of immunoglobulin G (IgG). This introduces a confounding effect on co-IP experiments on intact 
proteins.  Instead, I propose two experiments.  Ectopic expression of each protein with 
expression tags in a model mammalian cell line, such as HEK293, may allow for more specific 
co-IP than in systems that I am currently using.  If the confounding effects of IgG are not 
reduced in this system, a mammalian two-hybrid reporter assay may provide quantitative 
analysis of VDR/Hic-5 binding, including efficiency of reporter transactivation (260).  Within 
either system, I would be able to delete domains from each protein in order to determine which 
are necessary for interaction.  Previously, the LIM4 domains of Hic-5 were shown to interact 
with the tau2 transactivation domain within GR (208).  Given the structural similarities between 
members of the nuclear receptor superfamily, I would expect the LIM4 domain of Hic-5 to 
interact with the C-terminal AF-2 transactivation domain of VDR. 
The differential effects of Hic-5 on VDR activity within epithelial and stromal 
compartments of prostate cancer presented an in vitro context by which 1,25D3-induced growth 
inhibition of LNCaP cells was further sensitized by ectopic expression of Hic-5 in the tumor line 
and knockdown of Hic-5 in the stromal WPMY-1 line.  To translate this result to the clinic, it 
needs to be validated in an in vivo setting.  I propose grafting LNCaP cells ectopically expressing 
Hic-5 mixed with primary CAFs containing control knockdown or Hic-5 knockdown into 
 
85 
immunocompromised mice.  Upon formation of palpable tumors, I would castrate the mice, treat 
them intravenously with 1,25D3 and later measure tumor size, invasive capacity, and markers for 
stromal transdifferentiation.  Based on the results presented here, I predict that 1,25D3 treatment 
of mice containing LNCaP/Hic-5 xenografts mixed with CAFs of Hic-5 would induce the least 
tumor growth, inhibit invasion the greatest, and reduce expression of myofibroblastic markers.  
Previously, Neil Bhowmick, my collaborator at UCLA, attempted to mix LNCaP and 
LNCaP/Hic-5 cells with Scr and shHic-5 WPMY-1 sublines, but WPMY-1 growth outpaced 
LNCaP growth and prevented tumor formation.  The selection of primary CAFs, which were 
previously associated with tumors themselves, should improve the probability of forming 
palpable tumors in mice. 
Differential effects of Hic-5 in epithelial and stromal compartments of prostate cancer 
have profound consequences on activation of the VDR pathway in prostate cancer.  Much of the 
future work proposed here suggests critical work in understanding the interaction between VDR 
and Hic-5 and epithelial-stromal communication within the tumor microenvironment.  Results 
from these studies may eventually lead to targeted treatment of prostate cancer through multiple 
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